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Febrifugine and Isofebrifugine are alkaloids isolated from Dichroa febrifuga Lour and have 
been characterised to be active against malaria. However, as there is still some ambiguity 
surrounding isofebrifugine’s structure, febrifugine has generated a greater interest in the 
medicinal chemistry community as a lead compound for synthesising a new wave of 
antimalarial drugs.  For example halofuginone is the synthetic derivative of febrifugine and 
has recently shown higher activity against malaria than that observed for the parent alkaloid. 
Through extensive work, the development of new hybrid molecules containing features 
associated with febrifugine were investigated. This required efficient routes towards these 
analogues to be devised. Indeed, the synthesis of the non-commercially available 
halofuginone quinazolinone was accomplished, permitting a route for the production of novel 
halofuginone analogues. In addition X-ray crystallisation data was obtained for the natural 
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The Chinese plant Dichroa febrifuga came to prominence in the medicinal chemistry 
community in the mid-twentieth century, as its roots and the leaves had been used to treat 
ailments such as headaches and stomach cancer for centuries.2  Tests conducted on the plant 
revealed that its extracts had active components towards malaria induced fevers as well as 
stomach cancers. Later studies revealed that the activity of these extracts was due to the 
alkaloids febrifugine and isofebrifugine (Figure 1).  The discovery of these alkaloids spiked a 
great interest on the development of a synthetic pathway towards them. 
 
However, during the attempted characterisation and synthesis of these compounds, it was 
found that the determination of their relative and absolute stereochemistry raised some 
challenges.2 In addition, it was found that febrifugine and isofebrifugine interconverted via a 
retro-aza-Michael reaction (Scheme 1).3 As a result of this isomerisation, mistakes concerning 
the precise structure of these alkaloids were made. However, these were later resolved 




The aim of this thesis is to focus on the development of synthetic methods towards 
febrifugine analogues by the use of literature and novel methods, and to show how these 
analogues can be modified structurally compared to the parent febrifugine structure to meet 
the demands for successful drug candidates. 
5 FEBRIFUGINE AND ISOFEBRIFUGINE 
 
The alkaloids febrifugine and isofebrifugine have inspired a number of total syntheses 
because of their high activity for such diseases as malaria. In 1943, Koepfli et al. demonstrated 
that febrifugine possessed superior activity against malaria in comparison to pre-existing 
treatments.4 During Koepfli’s experiments, febrifugine extracts were shown to be active 
against plasmodium gallinaceum (the malarial parasite in poultry). It was later on discovered 
that febrifugine acted by impairing haemazoin formation required for the mutation of the 
malaria parasite.4   
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This discovery then spiked interest in the development of synthetic methods towards 
febrifugine, and this was to become an area of significant interest over the years.  In this 
section some of these synthetic routes will be described.  
5.1 KOBAYASHI’S ROUTE 
In 1999 Kobayashi et al. completed the first asymmetric synthesis of febrifugine. Their 
approach began by controlling the two stereogenic centres of the piperidine fragment, by 
employing a lanthanide-catalysed three component coupling reaction between the aldehyde 
1, 2-methoxyaniline and 2-methoxypropene, in aqueous media (Scheme 2).5 
The first step was carried out in the presence of ytterbium triflate (Yb(OTf)3) in aqueous THF 
to give the Mannich type anti adduct 2. This adduct was then treated with HF to remove the 
TBS protecting group and this was followed by an Appel reaction resulting in spontaneous 
cyclisation to form an N-protected piperidine adduct which was readily deprotected by 
cerium ammonium nitrate (CAN) to give 3.6 
The piperidine 3 was protected as its N-Boc group and was treated with lithium 
hexamethyldisilazide (LHMDS) and trimethylsilyl chloride (TMSCl). The resulting silyl enol 
ether was then brominated to give 4. The cross coupling reaction between the bromoketone 
4 and 4-hydroxyquinazoline was carried out using potassium hydroxide to give 5 which was 








Analysis of the synthetic febrifugine analogue by optical rotation revealed that the antipode 
of the naturally occurring (+)-febrifugine had been generated (Figure 2).5 This drove Kobayashi 
to then later synthesise the naturally occurring analogue by using the chiral ester 1b. 
Interestingly, the isomerisation problems encountered earlier (Scheme 1) were not met in the 
final products delivered by this route.  This was suggested to be due to the reduced exposure 
of febrifugine to HCl during the removal of labile Boc protecting group.6 
5.2 TAKEUCHI’S ROUTE  
In 1999 Takeuchi et al. also completed their first synthetic route to (±)-febrifugine (Scheme 
3), where they used the relatively cheap 3-hydroxypyridine as a starting material 6.7 This route 
consisted of the reduction of the pyridinium salt formed from the reaction between 6 and 
benzyl chloride to afford the 3-allyl-N-benzyl derivative 7. The benzyl group was replaced by 
a benzyloxycarbonyl group, by treating 7 with benzyl chloroformate (CbzCl). A Lewis acid 
catalysed Claisen rearrangement, which took place at room temperature, gave the piperidine-
3-one derivative 8. The reduction of 8 gave 9 as the sole product, this stereoselective 
reduction was studied computationally by a PM3 (Parameterized model number 3) 
calculation.7 
Bromination of 9 using N-bromosuccinimide (NBS) afforded the pyridine carboxylate 10, this 
intermediate was then reacted with potassium tert-butoxide, followed by a bromohydrin 
reaction using NBS and water to produce 11. The cross coupling reaction of the 4-
hydroxyquinazoline and 11 in the presence of potassium carbonate afforded 12, which 
through hydrogenolysis and isomerisation, gave the intended febrifugine structure. However, 
the final product was obtained in low purity, this was due to the small difference in solubility 




In 2000 Takeuchi et al. discovered an asymmetric route to piperidine 9 via the use of baker’s 
yeast. The yeast reduction of the 3-piperidone derivative 8 produced the chiral piperidine-3-
ol intermediate 9 (Scheme 4) in a high yield and in high enatiomeric purity. This result also 
played a major role in determining the absolute configuration of isofebrifugine as (2S, 3S).8 
Furthermore Takeuchi found that the use of the 2-methoxy derivative 13 improved the yield 




Takeuchi and his team then examined the isomerisation of febrifugine and isofebrifugine in 
order to determine a method for isolating pure febrifugine analogues.8 This study involved 
exposing these compounds to various solvents including toluene, DMF, pyridine, EtOH, water 
and 10% HCl (aq). Heating the isolated analogue 12 at 80 °C for 30 min in water resulted in 
the largest ratio (2:1) of febrifugine to isofebrifugine among the selected solvents. On the 
other hand, the epimerisation of 12 in 10% HCl was not observed under the same conditions. 
Based on these results, Takeuchi was able to isolate pure febrifugine as the hydrochloride salt 
and its analytical properties were found to be identical to those reported for the natural 
product.8 
5.3 TANIGUCHI AND OGASAWARA’S ROUTE  
Taniguchi and Ogasawara demonstrated an alternative method to febrifugine, where they 
utilised chiral building blocks to assemble these molecules with control of absolute and 
relative stereochemistry.9 Their route was based on the proposal that the piperidine moiety 
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16 could be formed over several steps from an enantiomerically pure chiral building block 15, 
which could in turn be prepared from furfural 14 (Scheme 5).9   
 
The diol 16 was transformed regioselectively into the primary sulphide 17, when reacted with 
diphenyl disulfide in pyridine in the presence of tributylphosphine (Scheme 6). After 
benzylation of the secondary hydroxyl functionality, the benzyl ether obtained was converted 
into the sulfoxide which was heated at reflux in diphenyl ether in the presence of calcium 
carbonate to furnish the terminal olefin 18.  
During their experimental work Taniguchi et al. found that the direct epoxidation of the olefin 
18 with a peracid proceeded very slowly. Therefore 18 was converted into the epoxide 19 via 
dihydroxylation, monotosylation and base induced cyclization which in turn produced an 
inseparable mixture of diastereoisomers of 19. The mixture was then reacted with the 
potassium salt generated from the 4-hydroxyquinazoline to furnish the secondary alcohol 20 
as an inseparable mixture of diastereoisomers. This mixture was oxidised with Dess-Martin 
periodinane to give the protected febrifugine 21 as a single product. Heating 21 at reflux with 




Even though Taniguchi and Ogasawara’s route was successful in synthesising a pure analogue 
of the natural (+)-febrifugine, they were only able to obtain a yield of 11% over a total of 24 
steps, hence a more efficient route would be more beneficial.9 
5.4 BURGESS’ ROUTE 
Burgess et al. developed a synthetic route towards (+)-febrifugine analogues that employed   
N-acyl iminium ions, generated in the presence of Lewis or BrØnsted acids, for the key carbon-
carbon bond construction step.10 The N-acyl iminium precursor 22 (Scheme 7) was 
synthesised from N-carbethoxy-1,-2,-3,-4-tetrahydropyridine via an intermediate epoxide. 
The strategy was to introduce the silyl enol ether 24 which would in turn be generated by the 
N-alkylation of the 4-hydroxyquinazoline with chloroacetone and trapped by the introduction 






The initial coupling of the epoxide 22 and silyl enol ether 24 was accomplished by treatment 
with titanium tetrachloride (TiCl4) to generate a mixture of separable diastereoisomers 25. 
After the separation of the diastereoisomers via chromatography, potassium hydroxide was 
added to deprotonate the basic amine to yield the natural product analogue 26 in a 10% 
yield.10 
Burgess’s strategy provided a convenient method to generate (+)-febrifugine analogues. For 
example, the electronic effects of the 4-hydroxyquinazolinone could be explored by coupling 
various analogues to the piperidine epoxide. Even though the route was low yielding, 
Burgess’s method proceeded with high stereoselectivity. 
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5.5 RUTJES’S ROUTE 
 
Rutjes et al. developed complementary chemoenzymatic approaches for the rapid 
construction of hydroxypiperidine scaffolds, which resulted in the enantioselective synthesis 
of either enantiomer of febrifugine. Their work commenced with the reductive cyclization of 
cyanohydrin 27 (Scheme 8), followed by diazotisation to form 28. In their initial approach they 
focused on introducing the quinazoline side chain as the corresponding stannyl enol ether 29, 
however their strategy was unsuccessful despite trying a variety of conditions and Lewis 
acids.11 
Rutjes then anticipated that the side chain could be built in two steps, first by introducing a 
2-(chloromethyl)allyl moiety to form 30. This was then followed by the nucleophilic 
displacement of the chloride by the quinazoline nucleophile to form the febrifugine adduct 
31 at an 81% yield.11 However, the reduction of the lactam carbonyl proved difficult and 
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various methods failed to successfully lead to the selective reduction to the desired piperidine 
system, so this initial idea was abandoned. 
The group then chose a slightly longer and more linear synthetic route which involved building 
the side chain to attach the piperidine moiety 28 gradually by reacting it with 
allyltrimethylsilane and BF3.OEt2 to give the lactam 32 as a 4.2:1 mixture of cis/trans isomers 
(Scheme 9). After chromatographic separation, the cis-isomer was reduced with lithium 
aluminium hydride (LiAlH4). The newly formed amine was then protected with a Boc group 
and the alcohol was converted to a methoxymethyl ether (MOM) group to give 33 in a good 
yield. The subsequent mCPBA mediated epoxidation followed to afford 34 as a 2.5:1 mixture 
of diastereoisomers.11 
The epoxide was then opened with sodium azide, followed by Staudinger reduction to form 
the amine 35. The reaction of the amine with isatotic anhydride (Et3N, EtOAc, 40 oC) led to 
the introduction of anthranilic acid and the hydrolysis of the MOM ether afforded the desired 
amide 36. The quinazolinone moiety was then formed via a condensation reaction under the 
influence of triethyl orthoformate (CH(OEt)3) in toluene at elevated temperatures to give 37. 
The final step involved Dess Martin periodinane oxidation and protecting group removal to 





The overall yield for this synthetic route was 2.5%, however as it utilised cheap starting 
materials, the route was thought to offer various possibilities for the preparation of many 
different synthetic analogues.11 Recently Rutjes et al. have developed an alternative strategy 
were febrifugine is synthesised in a 32% yield in ten steps (Scheme 10). The high efficiency of 
this route was considered to be due to the high selectivity in the N-acyliminium ion reaction, 
which reduces the epimerization of isofebrifugine into febrifugine considerably. However, the 
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starting materials were not easily accessible therefore there were fewer possibilities for the 
synthesis of novel analogues.12 
 
Nevertheless, this alternative route did comprise of similar steps to the preliminary synthetic 
route (Scheme 8). For example the N,O-acetal 39 was coupled to 2-(chloromethyl)allylsilane 
in the presence of BF3.OEt2 to afford 40. The febrifugine skeleton 41 was then completed via 
the coupling reaction between 40 and the deprotonated quinazolinone intermediate. 
Subsequent quantitative ester saponification was achieved by sodium hydroxide, followed by 
a Barton decarboxylation, involving the mixed anhydride formation, coupling with thiolactam 
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and tBuSH mediated radical removal of the carboxylate producing 42.11,12 The oxidative 
cleavage of 42 with osmium tetraoxide and sodium periodate, followed by the hydrogenolysis 
of the Cbz-protection group yielded the final febrifugine structure. 
6 FEBRIFUGINE   ANALOGUES AS ANTIMALARIAL TREATMENTS 
 
Malaria is widely regarded as the most severe protozoal disease, as it is one of the most 
common infectious diseases and is found in at least 100 tropical and subtropical countries. 
The most common strain found in humans is plasmodium falciparum and is known to kill on 
average a total of 3 million people a year.1 Consequently, the greatest defence against malaria 
would be a long lasting vaccine, as there is an increasing demand for medicinal agents which 
will overcome the increasing number of epidemics caused by resistant strains. 
Based on the early studies by Koepfli, febrifugine was initially regarded as an important 
breakthrough in the fight against malaria. However, side effects such as nausea, vomiting and 
liver toxicity have prevented its use as a potential clinical drug. Febrifugine’s toxicity was 
proposed to be due to the metabolic oxidation of the alkaloid in the host by biomolecules 
such as the cytochrome P-450 enzymes. This oxidation process produces highly reactive 
epoxides (Scheme 11). These short lived electrophilic oxides are assumed to form covalent 
adducts with DNA, RNA, proteins or other biomolecules inside the host during their 





Consequently, in 2002 Kikuchi discovered, through antimalarial screening, that febrifugine 
analogues bearing a modified 4-quinazolinone ring were also active, while analogues 
produced through the modification of the side chain attached at the N-3 position of the 
quinazolinone ring were ineffective (Figure 3).14  
Kikuchi was able to access a number of febrifugine and isofebrifugine analogues through 
chemical synthesis. For example 44 - 46 were synthesised in order to investigate the role of 
the benzene moiety and nitrogen atom of the quinazolinone ring in the molecule’s bioactivity 
(Figure 3). The antimalarial activity of these analogues against P.flaciparum (FCR-3 strain) and 
the cytotoxicity against mouse mammary FM3A revealed moderate activity in the latter (EC50 
= 6.0 × 10-7, 9.0 × 10-8, 5.0 × 10-7 and 2.1 × 10-6 M). However they showed no selectivity against 





Examination of the analogues 47 - 48 revealed how modification the piperidine ring of 
febrifugine resulted in a loss of activity. Kikuchi et al. also synthesised 49 - 51 to determine 
the importance of the length of the connecting linking carbon chain between the piperidine 
structure and quinazolinone; it was discovered that the increase in length resulted in 
complete loss of activity.14 
However, Kikuchi’s main intention for his work was also to examine the structure-activity 
relationship (SAR) studies of Takaya’s bicyclic febrifugine analogues 52 and 53 (Figure 4). 
These analogues had exhibited excellent antimalarial activity, with high selectivity against the 
malarial parasite. Therefore, a large number of synthesised analogues of 52 and 53 each 
containing different functional groups were studied in order to develop potent 




In 2003 Hirai reported the isolation and the synthesis of the metabolic products of febrifugine 
(56 and 57) and Takaya’s analogue 52 (metabolites 58 and 59). His objective was to investigate 
the antimalarial activity of the metabolites and their analogues in order to synthesise 




The in vitro antimalarial and cytotoxicity assays using the synthetic compounds demonstrated 
that 56 and 58 had superior activity against the P.flaciparum strain as compared to 
compounds 57 and 59. Hirai’s results suggested that the basicity of both the nitrogen atoms 
on the quinazolinone and piperidine structures had a crucial effect on the overall activity 
against malaria. Nonetheless, as no serious side effects were observed with compound 56, 
this metabolite was discovered to be a promising lead compound in the development of a 
new type of antimalarial drugs.15 
In 2005 Michael et al. focused on the synthesis of the simpler deoxyfebrifugine analogue 60 
(Figure 6), even though this analogue was known to be inferior to febrifugine in in vitro 
antiplasmodial assays.17 Michael’s interest had stemmed from the fact that the deoxy 
analogue 60 had similar antimalarial activity to quinine, therefore a direct synthesis of 
deoxyfebrifugine and its analogues would provide alternative promising lead compounds for 
future study.18 
 
Zhu et al. also examined various ways of improving the biologically activity of febrifugine 
analogues through structural modifications.19 Their research focused mainly on the 4-
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quinazolinone moiety as it was earlier determined to be crucial for the antimalarial activity of 
febrifugine.  The aim of their research was to prevent the oxidation of this moiety to the 
corresponding arene oxide by cytochrome P-450 enzymes (Scheme 11). Zhu found that the 
only way to make this oxidation process unfavourable was to block the C-5 or C-6 positions of 
the quinazolinone ring. 
 
Based on this hypothesis, Zhu and his team successfully designed compounds bearing various 
substituents at the C-5 and C-6 positions (Figure 7) to prevent unwanted metabolic 
degradation.20 Subsequently as the synthesised compounds resembled febrifugine they were 
expected to have the same or similar mode of action, but were also expected to be less likely 
to produce toxic intermediates. The synthesised compounds 61 - 66 (Figure 8) were tested in 
vitro against two P.falciparium malaria parasite clones W2 and D6. The W2 clone was found 
to be susceptible to mefloquine but resistant other antimalarial drugs such chloroquine, 
sulfadoxine, primethamine and quinine, whereas the D6 clone was naturally resistant to 
mefloquine but susceptible to the rest of the drugs.21, 22 
The in vitro toxicology studies were carried out in isolated rat hepatocytes which are widely 
used in drug metabolism and toxicity studies.23 Chloroquine and febrifugine were also 
screened in W2, D6 and rat hepatocytes as positive controls. The results revealed that 
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compounds 61 and 62 showed potency against both the chloroquine sensitive malarial strain 
(D6) and chloroquine resistant malarial strain (W2). It was also discovered that these 
compounds were over 100 times less toxic compared to the parent febrifugine analogue. On 
the other hand, compounds with electron withdrawing groups on the C-6 position or bulky 
substituents (63 - 66) had both decreased antimalarial activity and toxicity. 
 
In 2012 Zhu et al. then discovered that the original piperidine ring could be replaced by a 
pyrrolidine ring and that the presence of the 3’methylene group was not essential for 
antimalarial activity by successfully synthesising and evaluating compounds 67 - 69. The 
compounds still resembled febrifugine by possessing a planar aromatic ring, a 1-amino group 
and C - 2’, C - 3’ O functionality, therefore they were still expected to exhibit a similar mode 
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of action as the previous analogues. However, the other major difference to their structure 
was that they also possessed alkoxy groups on the pyrrolidine moiety, hence making them 
more lipophilic.19 
The synthesised compounds 67 - 69 were also found to display superior and equally potent 
antimalarial activity against chloroquine sensitive and resistant malaria strains as compounds 
61 - 66. However, the antimalarial potency was found to be improved when the lipophilicity 
of the compound was increased.  Therefore, further studies led to compounds 67 and 68 to 
be identified as having excellent efficacy in relevant primate models and were found to 
possess a wider therapeutic index than other commonly used antimalarial drugs.19 
7 FEBRIFUGINE ANALOGUES AGAINST IPF 
 
Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease within the group of idiopathic 
interstitial pneumonias. It is a distinct clinical entity occurring in adults and is limited to the 
lungs.2 The disease affects approximately 5 million people globally and appears to be 
increasing in prevalence. Despite recent advances, IPF remains generally resistant to current 
drug therapies and is invariably fatal, with median survival of 3 - 5 years. Even though the 
current treatments for IPF, pirfenidone and nintedanib, have been proven to slow the decline 
of lung function, their effects on the long term prognosis of the disease are still unknown.42 
This together with the emerging evidence of different phenotypes in IPF and the lack of 




Recently halofuginone (Figure 9), the halogenated derivative of febrifugine, has been tested 
in clinical trials as a potential therapeutic towards fibrotic diseases such as IPF. This alkaloid 
analogue was shown to inhibit the formation of excess collagen in mouse models, by 
preventing differentiation of the fibroblasts to myofibroblasts.42  As a result, a reduction in 
fibrosis was observed, which also improved physiological parameters such as regeneration in 
cirrhotic liver, cardiac and respiratory performance. Studies by Zhou have also reported how 
halofuginone inhibits TH17 cell differentiation by activating the amino acid response pathway, 
by inhibiting human prolyl - transfer RNA synthetase (ProRS) to cause intracellular 
accumulation of the uncharged tRNA. This is hypothesised to decrease the submucosal 






Since Zhou’s theory involved the presence of unhydrolysed ATP, Zhou and his team developed 
a binding model showing halofuginone forming extensive hydrophobic contacts and hydrogen 
bonding interactions with ProRS and ATP. This previously mentioned work highlights the 
importance in developing an efficient synthetic route towards febrifugine derivatives, as they 
could serve as a basis for new treatments and hopefully be possible drug candidates.  
8 OUR WORK 
 
The aim of our work was to generate an efficient route towards febrifugine analogues such 
as halofuginone in the hope of developing novel hybrid analogues. In order to synthesise 
halofuginone, a synthetic route towards its quinazolinone unit (Figure 10) had to be devised, 
as this compound was not commercially available at the start of the project. 
 
The initial step was to find a literature route towards this molecule, a SciFinder Scholar search 
revealed that only one patented route has been reported (Figure 11). This route began with 
the bromination of the aromatic ring with bromine and a catalytic amount of iron chloride in 
n-butyl bromide. The oxidation of the methyl group with potassium permanganate (KMnO4) 
then followed. The amination of the bromide using ammonium hydroxide and copper oxide 
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then afforded the aminated product. The reaction of the synthesised aminated product with 
formamide then delivered the intended quinazolinone intermediate. 
 
When we employed the reported conditions for the bromination of m-chlorotoluene, the 
intended product was obtained in a 31% yield. Interestingly, changing the solvent to the less 
toxic dichloromethane increased the yield to 56% (Scheme 12). 
 
However, the subsequent permanganate mediated oxidation of the methyl group under the 
reported conditions proved problematic as the starting material was recovered in almost all 
cases (Table 1, entry 1). The ineffectiveness of this step was thought to be due to both the 
decomposition of the oxidant and the insolubility of the starting material. 
 Therefore, the use of ethyl acetate as a co-solvent and addition of the oxidant portion wise 
was considered, unfortunately the product was obtained in low yield (Entry 2). In addition, 
the use high equivalents of permanganate and employing tetra-n-butyl ammonium bromide 
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as a phase transfer catalyst also proved unsuccessful (Entry 3). Recourse to alternative 
conditions such as the employment of vanadium (IV) oxide sulfate (VOSO4), cobalt acetate 
(Co(OAc)2) and manganese acetate tetrahydrate (Mn(OAc)2.4H2O) catalysts also failed to 
promote oxidation (Entries 4, 5, 6). Consequently, the idea of brominating the methyl group 
and hydrolysing the resulting tribromomethyl group was investigated (Figure 12). 
 
Reacting 4-bromo-5-chlorotoluene with NBS, azobisisobutyronitrile (AIBN) in carbon tetra 
chloride (CCl4) and irradiating the mixture with a tungsten lamp without external cooling while 
stirring for 4 hours did not give the tribrominated product, however the dibromomethyl  
product was produced in a 60% yield (Table 2, entry 1). Reducing the time of irradiation to 3.5 









Entry Conditions Yield (%) 
1 KMnO4 (2 eq), H2O, reflux, 16 h 0 
2 KMnO4 (8 eq), H2O ,EtOAc , reflux, 16 h 2 
3 KMnO4 (20 eq), C16H36BrN (0.6 eq), H2O, EtOAc , reflux, 72 h 3 
4 AcOH, HBr , VOSO4 (3 eq), 100 °C, 20 h 0 
5 Co(OAc)2.4H2O (0.6 eq), Mn(OAc)2.4H2O (0.2 eq), AcOH, 130 °C, 6 h 0 
6 Co(OAc)2.4H2O (1 eq), Mn(OAc)2.4H2O (0.5 eq), AcOH, 130 °C, 6 h 0 
      All reactions were conducted on a 0.3 mmol scale. 
As CCl4 is a classed human carcinogen, a brief solvent screen was conducted in an effort to 
find a more suitable reaction medium. The use of dichloromethane afforded the product in 
67% yield, however the monobrominated compound was also formed (entry 2). When a more 
environmentally friendly solvent such as ethyl acetate was used, the monobrominated 






Entry Solvent Time (h) Yield (%) of 78 Yield (%) of 79 
1 CCl4 4 60 0 
2 CCl4 3.5 0 0 
3 CH2Cl2 4 67 20 
4 EtOAc 4 0 64 
  
As dichloromethane produced the product in a good yield and was less toxic than carbon 
tertrachloride, the conditions listed in entry 3 of table 2 were used. With these conditions in 
hand the hydrolysis of the dibrominated product to form the corresponding aldehyde was 
investigated (Table 3). 
 
Entry Solvent Temp. °C Time (h) Yield (%) 
1 DMSO 120 72 h 89 




Heating dibromide 78 in DMSO provided the product in 89% yield (entry 1, table 3). 
Introducing water as a co-solvent reduced the reaction time to 16 h and delivered the product 
in a similar yield (entry 2). 
With the aldehyde 80 in hand, the oxidation step to the corresponding acid was carried out 
(Table 4). Oxone was used as an oxidant and it was found that increasing the equivalents of 
this oxidant, increased the overall yield of the product (Table 4, entries 1-3). 
 
Entry Oxidant Solvent Time (h) Yield (%) 
1 Oxone (1 eq) DMF 16 h 0 
2 Oxone (4 eq) DMF 48 h 85 
3 Oxone (5 eq) DMF 48 h 91 
 
The next step was the amination of the 2,4-dibromo-5-chlorobenzoic acid to produce the 
aminated product. The use of ammonium hydroxide and a catalytic amount of copper oxide 




Finally, this product was then reacted with formamide to produce the quinazolinone 
intermediate in a 60% yield (Scheme 14). Having successfully synthesised the desired 
halofuginone quinazolinone 83, we then turned our attention to the coupling reactions 
required to synthesise halofuginone and febrifugine analogues. 
 
9 SYNTHESIS OF FEBRIFUGINE DERIVATIVES 
 
Before attempting to syntheses halofuginone, our preliminary goal was to synthesise a 
selection of febrifugine analogues using the commercially available febrifugine quinazolinone. 
The synthesis of these analogues would then provide a pathway to multiple derivatives, 
including halofuginone. Initially Burgess’ method (Scheme 7) was considered as it represented 




The first step in our synthetic route was to couple the quinazolinone to chloroacetone, which 
produced the 3-(2-oxopropyl) quinazolin-4(3H)-one 84 in a 93% yield (Scheme 15). This 
ketone was reacted with trimethylsilyl trifluoromethane sulfonate (TMSOTf) and Hünig’s base 
(DIPEA) to produce Burgess’ silyl enol ether 24 in a 66% yield, this was to be used in the next 
step without further purification. As the optimisation of this route was being investigated, the 
synthesis of the piperidine epoxide 86 was also explored. The epoxidation of the Boc 
protected piperidine 85 with dimethyl dioxirane (DMDO) 87 was envisioned (Scheme 16). 
Unfortunately, after the reaction of acetone, oxone and sodium bicarbonate it was difficult 
to obtain sufficient quantities of the DMDO product after distillation, hence an alternative 
method was devised (Scheme 16). 
 
The method envisaged involved coupling the silyl enol ether 24 with a diacetate compound 
88 under Lewis acidic conditions (Scheme 17). The initial step consisted of the dihydroxylation 
of 85 using osmium tetroxide followed by acetylation, which afforded the diacetate 88 in a 




Having optimised the synthesis of the silyl enol ether 24 and diacetate piperidine 88, we were 
in a position to investigate the coupling reaction. Using Burgess’ conditions of introducing 
three equivalents of TMSOTf to 88 and then adding the silyl enol ether 24, we were able to 
obtain the febrifugine analogue 90 and its corresponding diastereoisomer 91 (Scheme 18), 
albeit in a low yield. 
 
The cause of the low yield and the consequent amine deprotection was determined to be due 
to the use of an excess amount of the Lewis acid, which in turn coordinated to both acetate 
groups and the Boc carbonyl group, leading to the formation of triflic acid (Scheme 19). The 





Therefore, a Lewis acid screen was conducted in an effort to avoid the loss of the Boc group 
in the hope that the protected febrifugine analogue would be obtained (Table 5). In the event, 
relatively weak Lewis acids (ZnCl2, ZnBr, Et2AlCl, FeCl3, Cu(CF3SO3)2, Sc(OTf)3) did not afford 
any product, whilst the stronger promoters (TiCl4, BF3.OEt2) gave the deprotected piperidine 





Entry Lewis acid Yield (%) of 90 Yield (%) of 91 
1 TMSOTf (3 eq) 13 7 
2 TMSOTf (1 eq) 33 15 
3 ZnCl
2 
(1 eq) SM recovered - 
4 TiCl
4
 (1 eq) 25 7 
5 ZnBr
2





 (1 eq) 19 20 
7 Et2AlCl (1 eq) SM recovered - 
8 FeCl3 (1 eq) SM recovered - 
9 Cu(CF3SO3)2 (1 eq) SM recovered - 
10 Sc(OTf)3 (1 eq) 8 16 
 
Through NMR analysis of the reaction mixture, it was found that both cis and trans products 
were formed. Their relative stereochemistry was determined by 1H NMR spectroscopy using 
Karplus’ equations. The splitting patterns for the respective isomers are shown in Figure 13. 
The trans isomer should exhibit large trans-diaxial coupling for the proton highlighted, while 
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the cis isomer should show smaller axial-equatorial coupling. In the event we assigned the 
compound with a broad multiplet at 4.56 ppm as product 90, whereas compound 91 showed 
a narrow multiplet at 4.95 ppm. 
 
The formation of both isomers could be due to product epimerisation via the retro-aza-
Michael process, or an inherently unselective addition reaction. Notwithstanding these 
optimisation studies, the best yield obtained was 33% (Table 5, Entry 2). Considering the low 
yields obtained via this route, an alternative pathway was envisaged. 
The alternative strategy to be undertaken was inspired by Zhu’s method for synthesising 
febrifugine analogues (Scheme 20).21,22 This route employed the epoxidation of the allylated 
compound 92, followed by coupling of the corresponding epoxide 93 to the quinazolinone to 




The initial step in our route was to couple the diacetate compound 88 with allyltrimethylsilane 
at -78 °C, using BF3.OEt2 as the Lewis acid (Table 6, entry 1). This reaction only provided the 
deprotected product 95 as a mixture of both cis and trans isomers in a low yield. Even when 
the quantity of the Lewis acid decreased to one equivalent (Table 6, entry 2), the yield was 
only increased by 5%, with a mixture of both cis and trans isomers once again being 
generated. The use of stronger Lewis acids (TiCl4, TMSOTf) also afforded the product as a 
mixture of isomers in low yields (Table 5, Entries 3 and 4). 
 
Entry Conditions Yield (%) Cis and Trans ratio 
1 BF3.OEt2 (4 eq) 5 1 : 1 
2 BF3.OEt2 (1 eq) 10 1 : 1.2 
3 TiCl4 (4 eq) 12 1 : 1.8 




The poor yields and low stereocontrol associated with the allylation route prompted us to 
consider the coupling of the diacetate 88 with a chloro silyl enol ether 96 (Scheme 21). The 
coupled product 97 would then be reacted with the quinazoline to form the febrifugine 
derivative 89. In order to accomplish this route, the silyl enol ether 96 had to be synthesised 
and the initial notion was to react chloroacetic anhydride with ((trimethylsilyl) methyl) 
magnesium chloride to form the intermediate 98, followed by a Pd-catalysed Brooke 
rearrangement to afford the intended silyl enol ether 96 (Scheme 22). Table 7 summarises 





Reacting chloroacetic anhydride with one equivalent of ((trimethylsilyl) methyl) magnesium 
chloride for one hour returned only starting material (Table 7, entry 1), whilst using an excess 
of the Grignard afforded a complex mixture of products (Entry 2). Varying the time to 72 hours 
allowed the reaction to reach full conversion, however the yield of product obtained was low. 
 
Entry Equivalents of 
Grignard 
Time (h) Yield (%) 
1 1 1 0 
2 3 1 Complex mixture 
3 1 72 10 
 
With a small amount of the product in hand, we decided to study the next step which was the 
Brooke rearrangement. Unfortunately, after numerous attempts the product could not be 
obtained. Therefore, we explored an alternative route to the chloro silyl enol ether 96 via the 




Deployment of literature conditions resulted in the product being produced in poor yields 
(Table 8, Entry 1). Consequently, an attempt to improve the yield by the use of TMSOTf 
instead of TMSCl was considered, as a result an increase in the yield was observed (Entry 2). 
Changing the solvent to dichloromethane increased the yield further to 21% (Entry 3). 
However, the reaction produced a mixture of 96 and 99, and separation of the desired 
product from the mixture proved to be difficult. Therefore, a brief screen of hindered bases 
was conducted to see if the silyl enol ether 96 could be formed selectively over the by-product 














Entry Solvent Lewis acid Base Yield (%) Ratio of 96 : 99 
1 MeCN TMSCl LiHMDS 5 1 : 6 
2 MeCN TMSOTf LiHMDS 10 1 : 4.5 
3 CH2Cl2 TMSOTf LiHMDS 21 1 : 5.4 
4 CH2Cl2 TMSOTf 2,6 Lutidine 57 1 : 6.1 
5 CH2Cl2 TMSOTf DBU 24 1 : 9.1 
6 CH2Cl2 TMSOTf LDA 20 1 : 16 
The ratios of 95 and 98 were judged by 1HNMR spectroscopy of the crude reaction mixture. 
When 2,6 lutidine was used the yield increased to 57% and a higher ratio of 99 was observed 
(Table 8, Entry 4). Unfortunately however, exploring other hindered bases such as DBU and 
LDA failed to improve selectively towards 96 (Entries 5 and 6). 
Inspection of the literature highlighted that the enol ether 99 was in fact the 
thermodynamically more stable isomer, while 96 was formed under kinetic control. This work 
suggested that the selective synthesis of the kinetic enol ether was challenging, as the 
thermodynamic product was formed in almost every case. Therefore, the synthesis of 100 
from the symmetrical 1,3-dichloropropan-2-one was then considered (Scheme 24). The initial 
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idea was that the enol ether 100 would react with the diacetate piperidine 88 to form the 
intermediate 101. This intermediate would the react with the quinazolinone to form the 
analogue 102, which in turn will be reduced to form the febrifugine analogue 89. 
 
In order to generate 100, 1,3 dichloropropan-2-one and TMSCl were combined in the 
presence of triethylamine in ether; however only the starting material was recovered (Table 
9, Entry 1). Changing the base to LDA showed no improvement to the reaction as the starting 
material was again recovered (Table 9, entries 2 and 3). This route was therefore abandoned 









Entry Conditions Yield (%) 
1 Et3N (1 eq), Et2O, 16 h 0 
2 LDA (1 eq), THF, 3 h 0 
3 LDA (1 eq), THF, 16 h 0 
 
The alternative route focused on coupling 2,2-dimethyl-4-methylene-1,3-dioxolane  103 with 
the diacetate 88 , forming the intermediate 104 (Scheme 25). The hydrolysis of 104 would 
then produce piperidine analogue 105, which through tosylation would form the analogue 
106. The plan was then to couple 106 with the febrifugine quinazolinone to form the 




The dioxolane 103 was synthesised by reacting epichlorohydrin with an excess of acetone in 
the presence of a Lewis acid, which afforded the intermediate 107 in a 97% yield (Scheme 26). 
The 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane 107 was then reacted with KOH to produce 
103 in a 44% yield.34 
 
With the dioxolane 103 in hand, we investigated the key coupling reaction (Scheme 27). 
However, this step proved problematic as the product 105 was never obtained after 





As we were unable to develop an efficient route towards the febrifugine analogue 89, we 
decided to target different febrifugine analogues (Figure 14). The synthesis of these analogues 
required the piperidine 108 to be synthesised. We hoped that the β-dicarbonyl moiety in 108 
would facilitate a range of alkylation reactions. 
 
The route envisaged for the synthesis of 108 was based on literature precedent and consisted 
of a hydrogenation of 3-hydroxypyridine-2-carboxylic acid to form the 3-hydroxypiperidine-
2-carboxylic acid 109 (Scheme 28).36 The next step was the esterification of 109 to form the 
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corresponding ester 110. Protection of the ester with either the Boc or Cbz group followed by 
a Swern oxidation would then result in product 108 being produced. 
 
Hydrogenation of the 3-hydroxypyridine-2-carboxylic acid under the reported conditions was 
initially unsuccessful as the product 109 was not obtained. We believed that the use of lower 
hydrogen pressure (relative to literature conditions) during the reaction was responsible for 
this observation. Therefore, we decided to use the continuous flow hydrogenation reactor (H-
cube) as this allows a range of temperatures and hydrogen pressures to be accessed. 
Passing the reaction mixture through a rhodium on carbon (Rh/C) catalyst unfortunately 
failed to deliver product (Table 10, Entry 1). However, changing the catalyst to palladium 
hydroxide on carbon (Pd(OH)2/C) was more successful and the product was observed (Entry 




Entry Catalyst Yield (%) 
1 Rh/C 0 
2 Pd(OH)2/C 20 
Reactions run using a continuous flow hydrogenation reactor H cube. Each reaction was run under a pressure of 
80 Bar of H2 and temperature of 100 °C. 
Thus the esterification of the carboxylic acid was considered prior hydrogenation to aid the 
purification of the piperidine product (Table 11). The reaction of the 3-hydroxypyridine-2-
carboxylic acid with thionyl chloride in methanol did not yield product (Table 11, Entry 1). 
However, when the reaction performed in methanol with a catalytic amount of concentrated 
sulfuric acid, the corresponding ester 112 was produced in a 49 % yield (Entry 2). 
 
Entry Conditions Yield (%) 
1 SOCl2 (1 eq), MeOH (10 mL), rt 0 




Hydrogenation of 112 using the H-cube reactor with a palladium hydroxide on carbon catalyst 
produced the heterocycle 113 in a 97 % yield (Scheme 29). The next step towards the final β-
keto ester 108 was the protection of the amine in 113. Hence, with the amine was reacted 
with di-tert-butyl dicarbonate (Boc2O) in dichloromethane to afford the protected product 
114 in a 56% yield (Scheme 29). 
 
The final Swern oxidation was attempted under literature conditions (Table 12, entry 1), 
unfortunately however, the product was not obtained. Thus a scope of various oxidants and 
conditions were examined (Table 12). Oxidants such as Jones reagent, pyridinium 
chlorochromate (PCC), potassium permanganate and Dess-Martin periodinane (DMP) were 








Entry Conditions Yield (%) 
1 Oxalyl chloride (1.1 eq), DMSO (2.4 eq), Et3N (4.5 eq), CH2Cl2, 16 h 0 
2 Oxalyl chloride (3 eq), DMSO (2.4 eq), Et3N (4.5 eq), CH2Cl2, 16 h 3 
3 Jones reagent, rt, overnight 18 
4 PCC (2.5 eq), florisil, CH2Cl2, rt, 16h 4 
5 PCC (4 eq), florisil, CH2Cl2, rt, 16h 2 
6 KMnO4 (3 eq), MeCN, 16 h 0 
7 KMnO4 (3 eq), BF3.OEt2,  MeCN, 16 h decomposition 
8 DMP (1.5 eq), CH2Cl2, 16 h 0 
 
After failing to produce a significant amount of the keto ester 108, an alternative route was 
employed, again based on literature precedent (Scheme 30).38 The initial step was the 
reaction of pyrrolidinone with ethyl chloroacetate and sodium hydride in the presence of the 
phase transfer catalyst tetrabutylammonium bromide (TBAB) to form the pyrrolidinone 
intermediate 115 in a 50% yield. Heating 115 in 5 N HCl formed the diacid 116, which was 
converted to the corresponding ester product 117 by reacting it with acetyl chloride and 
methanol. Protection of the free amine with di-tert-butyl dicarbonate (Boc2O) afforded the 
diester 118 in a 40% yield. Cyclisation of 118 with potassium tert-butoxide (KtOBu) produced 




The next step in establishing routes to the analogues shown in Figure 15 was to select linkers 
which would allow the coupling reactions between the keto ester and the quinazoline to 
occur. The requisite linkers (Figure 15) were 3-chloro-2-(chloromethyl) prop-1-ene 119, 1,3-
dichloropropan-2-one 120 and 3,3-bis (bromomethyl) oxetane 121. Both 3-chloro-2-
(chloromethyl) prop-1-ene and 1,3-dichloropropan-2-on were commercially available, 
however the 3,3-bis (bromomethyl) oxetane was difficult to source and so this compound 







The initial step was to convert the pentaerythritol 122 to the tribromide intermediate 123, by 
reacting the erythritol with 48% hydrobromic acid in acetic acid and sulfuric acid (Scheme 
31).37 Through this reaction the product was obtained in a 53% yield. The intermediate 123 
was then predicted to undergo cyclisation in the presence of a base to form the intended 
oxetane. Therefore, a brief base screen was conducted to find the optimal conditions (Table 
13). 
The use of sodium ethoxide and sodium tert-butoxide in ethanol only yielded the product in 
low yield (Entries 1 and 2). However, changing the base to sodium hydride and the solvent to 
ether increased the yield to 30% (Entry 3). Increasing the temperature resulted in a sharp 
increase in the yield to 84% (Entry 4). Having established the optimal conditions for the 
synthesis of the bromo oxetane 121, the coupling reactions between the keto ester 108 and 




Entry Conditions Yield (%) 
1 NaOEt (1.5 eq), EtOH, reflux, 2 h 4 
2 NaOtBu (5 eq), EtOH, reflux, 2h - 
3 NaH (1 eq), Et2O, rt, 16 h 30 
4 NaH (1 eq), Et2O, reflux, 16 h 84 
 
The first reaction to be considered was the coupling of the oxetane 121 to the piperidine 108. 
A range of different conditions were investigated but unfortunately no product was observed 
(Table 14). This result was thought to be due to the steric hindrance around the oxetanyl 
bromides (neopentyl effect). Thus, the oxetane was slow to undergo bimolecular nucleophilic 







Entry Conditions Yield (%) 
1 NaH (1 eq), Oxetane (3 eq), DMF, rt, overnight 0 
2 NaH (1 eq), Oxetane (4 eq), DMF, rt, overnight 0 
3 K2CO3 (1 eq), Oxetane (2 eq), acetone, reflux, 12 h 0 
 
Coupling the keto ester 108 to 3-chloro-2-(chloromethyl) prop-1-ene 119 also proved 
unsuccessful as a complex mixture of products was obtained. A similar result was obtained 
when 1,3-dichloropropan-2-one 120 was coupled to the keto ester (Scheme 32). 
 
The unsuccessful coupling reactions prompted us to change the alkylating agent, in particular, 
moving away from the dichloride 120. We therefore decided to couple the quinazolinone to 
3-chloro-2-(chloro) methyl prop-1-ene 119 (Scheme 33). The reaction afforded the product 




The next step was to find conditions to couple 127 to the previously synthesised keto ester 
108 (Table 15). When sodium hydride was used as the base, the product 129 was not observed 
(Entry 1). Increasing the temperature did not improve the reaction as the starting materials 
were obtained (Entry 2). As a consequence, the allyl chloride was converted into the 
corresponding iodide via the Finkelstein reaction in the hope of improving the alkylating agent 
reactivity (Scheme 34). 
 
Entry Conditions Yield (%) 
1 NaH (1.6 eq), DMF, rt, 16 h 0 





With the iodo product 130 in hand, conditions for the coupling reaction with 108 were 
examined. However, coupling the Finkelstein product with the keto ester produced a complex 
mixture of products and the analogue 129 was not observed. We determined that the iodo 
product 130 was unstable, and it underwent self-polymerisation when exposed to the open 
air. Therefore, the synthesis of the more stable acetate analogue 131 from the chloride 127 





Reacting the chloride 127 with sodium acetate yielded the acetate product 131 in a 60% yield 
(Scheme 35).  Employing established Tsuji-Trost conditions, the key coupling reaction was 
next investigated (Table 16). The use of palladium chloride with potassium carbonate in water 
failed to afford product (Table 16, Entry 1). Changing the catalyst to Pd (dba)2 and the solvent 
to THF (Entry 2) also failed to generate product. Other catalysts such as palladium acetate 
(Pd(OAc)2) and tris(dibenzylideneacetone) dipalladium (Pd2(dba)3.CHCl3) were also examined, 





Entry Conditions Yield (%) 
1 PdCl2 (3 mol%), TBAB (3 mol%), K2CO3 (1 eq), H2O, 50 °C 0 
2 Pd(dba)2 (3 mol%), PPh3 (0.5 eq), K2CO3, THF, 40 °C 0 
3 Pd(OAc)2 (5 mol%), PPh3 (1 eq), DBU (1.5 eq), THF, reflux 0 
4 Pd2(dba)3.CHCl3 (2.5 mol%), PPh3 (0.2 eq), NaH (1 eq), THF, rt 0 
 
We undertook a further retrosynthetic analysis of the febrifugine scaffold and decided to 
break the molecule into three components in the hope of developing a convergent pathway 
towards the target compounds (Figure 16). As the quinazolinone was commercially available, 
the main aspects to focus on were the synthesis of the chiral piperidine motif and central 
ketone. In terms of the piperidine structure, we decided to synthesise the epoxide from 
benzyl 3,4-dihydropyridine-1(2H)-carboxylate. However, to accommodate the reactive nature 
of the N-acyliminium ion, neutral epoxidation conditions were targeted. This prompted us to 
revisit the use of DMDO as Wallace had recently developed conditions to generate DMDO in 




Utilising Wallace’s conditions of adding acetone to an aqueous solution containing potassium 
peroxymonosulfate (oxone) and sodium bicarbonate proved successful as the epoxide 132 
was synthesised in a 83% yield (Scheme 36). The next step was to develop an alkylation 
approach to installing the central ketone in the febrifugine structure. This was achieved by re-
examining Rutjes’s route (Scheme 10) where the coupling reaction between the N,O acetal 
39 and the 2-(chloromethyl) allyl silane produced the chiral piperidine 40 in a good yield. 
 
Pleasingly, adopting these conditions the reaction between the epoxide and 2-
(chloromethyl)allylsilane proved to be successful in producing the trans product 133 in a 31% 




Due to the poor stereoselectivity of the reaction, alternative substrates were investigated in 
order to promote the selective synthesis of the trans product. The route envisaged was to 
introduce large groups to the piperidine motif which could favour trans-addition to the N-
acyliminium ion intermediate. Therefore, the analogues shown in Figure 17 were selected for 
this purpose. 
 
In order to synthesise the selected compounds in Figure 17, the diol 138 was targeted as a 







Carbonate 135 was synthesised by reacting the diol 138 with triphosgene in the presence of 
pyridine to give the product in a 64% yield (Scheme 39). The acetal 136 was successfully 
formed in a 54% yield by reacting 138 with acetone in the presence of a Lewis acid catalyst. 
137 was synthesised by previously established conditions mentioned earlier for the synthesis 
of compound 89, were the diol 138 was reacted with acetic anhydride, triethyl amine in the 
presence on a nucleophilic catalyst to give the 137 in a 86% yield.  
 
With the piperidine compounds in hand the next step was to investigate the coupling 
reactions with 2-(chloromethyl)allylsilane. The reaction with the carbonate 135 afforded the 
intended product, however this showed no selectivity as a 1.2 : 1 ratio trans to cis compounds 
was obtained (Scheme 40). Interestingly, the reaction of the acetal 136 with the 2-
(chloromethyl)allylsilane showed slight preference towards the cis diastereoisomer, this 
being produced as a 1 : 2 ratio trans to cis. Finally 137 also failed to show any selectivity 




The poor selectivities observed in the alkylation reactions was put down to the rapid 
equilibration of the conformers 138 and 139, and their similar rates of nucleophilic addition 




On the other hand, as we had successfully produced gram quantities of the both trans-alcohol 
133 and cis-alcohol 134 the coupling reaction with the quinazolinone was carried out (Scheme 
41). The commercial quinazolinone was reacted with the 133 in the presence of potassium 
carbonate to produce the analogue 140 in a 77% yield. Coupling with 134 was also successful 







In order to produce the central ketone the oxidative cleavage of the central alkenes were 
investigated. Utilising Rutjes conditions, osmium tetroxide and sodium periodate in a solution 
of THF and water were used to successfully produce the protected febrifugine analogues 142 






With the protected febrifugine analogues in hand, the next step was the removal the 
benzyloxy carbamate (Cbz) protecting group (Table 17). The use of boron tribromide and 
boron trichloride in dichloromethane failed to generate product (Entry 1 and 2). Changing the 
Lewis acid to trimethylsilyl iodide (TMSI) produced the febrifugine in a 20% yield (Entry 3). 
Whereas, subjecting 142 in neat 6 N HCl produced febrifugine 144 in a 22% yield (Entry 4). 
 
Entry Conditions Yield (%) 
1 BBr3 (1.5 eq) , CH2Cl2, rt, 16 h 0 
2 BCl3 (4 eq) , CH2Cl2, rt, 16 h 13 
3 TMSI (4 eq), CH2Cl2, rt, 3 h 20 
4 6 N HCl, reflux, 3 h 22 
 
We wondered if we could improve the product yield by using a stronger acid such hydrogen 
bromide. Therefore, using neat solution of hydrogen bromide (33 wt%) in acetic acid at 0 °C, 
we successfully produced the alkaloid in a 39% yield (Scheme 43). Even though the yield was 
moderate we found that recrystallization of the product generated fine crystals which allowed 
for the first X-ray crystal structure of febrifugine to be recorded. This crystal structure also 






Having established that the use of a strong acid was an effective means of removing the Cbz 
protecting group, the deprotection of the cis analogue was also carried out and isofebrifugine 
145 (34%) was produced (Scheme 44).    
 
In order to improve the yield of this step, we decided to isolate the HBr salt of the product 
and to consider the introduction of a solvent as a means of reducing any decomposition of 
starting materials that may occur due to high concentrations of acid. The protected 
febrifugine analogue 142 was therefore suspended in methanol and hydrogen bromide in 
acetic acid was added at 0 °C. This resulted in the successful formation of the hydrobromide 
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salt 146 in 89% yield (Scheme 45). These conditions were then repeated for the cis analogue 
143 unfortunately no product was generated. Instead, it was determined that the major 
product was the imine 148 (Figure 20). 
 
 
The assumption was that 148 was formed as a by-product during the epimerisation reaction 
of the cis analogue (Scheme 46). This result was supported by literature evidence which 
highlighted on how febrifugine and isoferbrifugine could interconvert via a retro-aza-Michael 
reaction under the influence of polar protic solvents (Scheme 1).3,8 Therefore, as a large 
excess of acid is used in our reaction, we believe that the Michael intermediate 150 is in 
equilibrium with the dicarbonyl compound 152 via the formation of the enol 151. The 
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dicarbonyl intermediate then cyclises to form 148. Attempts to record a crystal structure of 
148 failed due to the instability of the imine in both protic and aprotic solvents. 
 
 
Having, successfully established a route to the febrifugine hydrobromide salt, the synthesis 
of halofuginone hydrobromide was next considered (Scheme 47).  The coupling reaction 
between the trans 133 with our synthesised halofuginone quinazolinone 83 was well 
tolerated and produced the intended product 153 in an excellent yield. The oxidative cleavage 
using osmium tetoxide and sodium periodate produced the protected halofuginone 154 in a 
73% yield and the final deprotection step produced the halofuginone hydrobromide salt 155 





With a successful route towards febrifugine analogues, we next turned our attention to the 
synthesis of novel febrifugine analogues by using various quinazolinones. Our selected 
quinazolinones (Figure 21) were acquired from commercial sources (158 and 159) or obtained 
from previous developed Rh-catalyzed ortho-amidation cyclocondensation sequence 
developed in our group (156 and 157).39 The quinazolinones consisted of halide-swapped 




The coupling reactions between the different quinazolinones with the trans-piperidine 133 
proceeded smoothly, thereby providing an opportunity to access unique febrifugine analogue 
derivatives (Table 18). 
 
Entry Quinazolinone Product Yield (%) 






3 158  
 
71 






Having successfully coupled the key fragments, our final objective was to confirm that 
intermediates 160 - 163 could be taken forward to the corresponding febrifugine derivatives. 
We employed an oxidative cleavage and deprotection protocol, using our modification of the 
Rutjes route. We were pleased to find that the analogs 164 - 167 were all isolated in good 
yield under these conditions as the HBr salts (Figure 22). 
 
These encouraging results prompted us to further investigate other febrifugine analogues 
such as febrifuginol and epi-febrifuginol (Figure 23). Febrifuginol and epi-febrifuginol are 
synthetic analogues of febrifugine whereby the central ketone of febrifugine is converted into 
a hydroxyl functionality. These analogues were developed to overcome the facile 
interconversion of febrifugine and isofebrifugine via the retro-aza-Michael reaction (Scheme 
1). Moreover, febrifuginol and epi-febrifuginol were found to exhibit superior antimalarial 
activity in vitro in comparison to chloroquine and artemisinin.40,41 More recently, halofuginol 
was found to inhibit T helper 17 cells (Th17 cells), which in the future might be beneficial for 




Our aim was to slightly modify our already successful synthetic route towards febrifugine 
analogues. Primarily the protected febrifugine analogue 142 would have to be synthesised 
followed by the reduction of the central ketone and finally removal of the protecting group 
to furnish the fuginol hydrobromide salt (Scheme 48).  
 
 
The use of sodium borohydride to reduce 142 produced the hydroxyl product as 1 : 1mixture 
of diastereoisomers 168 (Scheme 49). These were separated by isocratic HPLC eluting with 
30% acetonitrile to 70% water to give 170 and 171. Both diastereoisomers were subjected to 
the deprotection conditions which produced both the febrifuginol and epi-febrifuginol 






Recrystallisation of 173 in methanol produced fine crystals which allowed for the first X-ray 
crystal structure of epifebrifuginol to be recorded, thereby confirming the stereochemistry of 
the hydroxyl group (Figure 24). The successful synthesis of the febrifuginol analogues inspired 
us to further alter the structure of febrifugine. Therefore, we devised a route towards 









10 PYRROLIDINE ANALOGUES 
 
A literature search on similar analogues led us to work developed by Zhu, where a library of 
pyrrolidine analogues were synthesised in an attempt to address the toxicity associated with 
the natural febrifugine alkaloid (Figure 25). The synthesised pyrrolidine analogues and their 
six membered counterparts were tested against P. falciparum clones W-2, a chloroquine 
resistant cell line for in vitro efficacy. 
 They found that most of the analogues exhibited comparable or superior in vitro and in vivo 
antimalarial activity compared to febrifugine. During their acute toxicity study they 
discovered that compound 174 was four times less toxic compared to febrifugine. Whereas 
compounds 175 - 179, where the aromatic ring has either nitrogen atom, an electron 
withdrawing group or a bulky group, revealed significantly reduced toxicity. Zhu’s impressive 




The first step was the epoxidation of the commercially available pyrrolidine 180 using 
Wallace’s conditions. In the event, the reaction was well tolerated forming the epoxide 181 
in a 65% yield (Scheme 50).The alkylation with the allyl silane produced 182 in a 60% yield as 
a 2 : 1 (cis : trans) mixture of diastereoisomers, which were separated via preparative HPLC 
eluting 40% acetonitrile to 60% water to give 183 and 184 (Scheme 51). Coupling the 
quinazoline component to each of the diastereoisomers proceeded smoothly producing 185 
and 186 in good yields.  
 
Both 185 and 186 were next subjected to the oxidative cleavage conditions and both products 
187 and 188 were produced successfully in good yields. Disappointingly however, the acid 
deprotection step proved difficult for both diastereoisomers as the decomposition of the 
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starting materials was observed for each case (Table 19, entries 1 and 2). Reviewing other 
deprotection conditions we had come across also failed to cleanly deliver the final products 















Entry Diastereoisomer Conditions Results 
1 187 HBr 33wt% in AcOH (100 eq), MeOH, 0 °C Decomposition 
2 188 HBr 33wt% in AcOH (100 eq), MeOH, 0 °C Decomposition 
3 187 6N HCl Decomposition 
4 188 6N HCl Decomposition 
5 187 Pd/ C, H2,  MeOH, rt,  Complex mixture 
 
These preliminary results suggested that our route would have to be modified to suit the 
sensitive nature of the pyrrolidine analogues. We also believe in order to further improve the 
methodology towards the 5 membered analogues, alternative protecting groups such as Boc 
should be used instead of the Cbz group.  
11 FUTURE WORK AND CONCLUDING REMARKS 
 
We have focused on developing strategies for the synthesis of febrifugine analogues by the 
use of literature and novel methods. For example, the use of Burgess’ route saw the synthesis 
of the novel febrifugine analogue 90, unfortunately the yields obtained via this route were 
low.10 Fortunately, after some optimisation, a successful route towards febrifugine analogues 
was realised, as the isolation of the final analogues such as 146, 155, 164, 165, 166 and 167 
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were achieved. Disappointingly, the attempts to synthesise the 5 membered analogues 
provide difficult as the intermediates were unstable under our deprotection conditions. 
This, recent research on febrifugine analogues has set the stage for future work on these 
compounds towards the development of a new wave of drugs with a wide therapeutic index 
e.g halofuginone.19,20 Therefore, we intend to continue with our efforts to find an efficient 




12.1 GENERAL PROCEDURES AND MATERIALS 
 
All the reagents used as received from commercial suppliers unless otherwise stated. 
Flash chromatography was performed on silica gel (Merck Kieselgel 60 F254 230 - 400 mesh). 
Thin layer chromatography (TLC) was performed on aluminium backed plates precoated with 
silica (0.2 mm, Merck DC-alufolien Kieselgel 60 F254) which were developed using standard 
visualizing agents : UV fluorescence (254 and 366 nm), potassium permanganate/ ∆. 
Melting points (m.p.) are of recrystallized materials and were recorded on Gallenkamp 
melting point apparatus and are uncorrected. 
1H NMR spectra were recorded on a Bruker AMX 400 (400 MHz) instrument supported by an 
Aspect 200 data system. Chemical shift (δ) are reported in ppm from tetramethylsilane with 
solvent resonance as the internal standard (CHCl3 in CDCl3 : δ7.27 ppm; H2O in D2O : δ4.60; 
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DMSO in (CD3)2SO : δ2.52). Data are reported as : chemical shift, multiplicity, integration, 
coupling constant (Hz), and assignment. 
13C NMR spectra were recorded using the JMOD pulse sequence on a Bruker AMX-400 with 
complete proton decoupling. Chemical shift are reported in ppm from tetramethylsilane with 
the solvent resonance as the internal standard (CDCl3 : δ77.0 ppm; (CD3)2SO : δ39.7). 
Infrared (FTIR) spectra were recorded on a Perkin Elmer Paragon 100 FTIR 
spectrophotometer, vmax in cm-1. 
Low resolution mass spectra (m/z) were recorded on either a Kratos MS 25 or MS 80 
spectrometer supported by a DS 55 data system, operating in EI, CI or FAB mode; or a Perkin-
Elmer Turbomass Benchtop GC-MS operating in either EI or CI mode, with only molecular ions 
(M+) and major peaks being reported with intensities quoted as percentages of the base peak. 
High-resolution mass spectra (HRMS) recorded for accurate mass analysis, were performed 
on either a MicroMass LCT operating in Electrospray mode (TOF ES); or a MicroMass Prospec 
operating in either FAB, EI or CI mode. 
12.2 SYNTHESIS OF HALOFUGINONE QUINAZOLINONE 
 
Synthesis of 4-bromo-5-chlorotoluene (76).31 
 
m-Chlorotoluene (2.5 g, 19.0 mmol) was added to a solution of FeCl3 (0.2 g, 1.2 mmol) in 
CH2Cl2 (50 mL) and the reaction mixture was cooled to 0 °C. Bromine (6.4 g, 40.0 mmol) was 
then added dropwise, whilst maintaining this temperature and the reaction was stirred for 2 
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h. The reaction was quenched with water and extracted with ethyl acetate. The combined 
organic layers were washed with NaHCO3 and then dried over MgSO4. The solvent was 
removed under reduced pressure to afford the crude product. Recrystallization of the crude 
product in petroleum ether yielded the title compound as a colourless solid (3.2 g, 71%) Mp 
68 - 70 °C (lit. Mp 92 - 95 °C); δH (400 MHz, CDCl3) 7.78 (s, 1H), 7.35 (s, 1H), 2.30 (s, 3H); δC 
(101 MHz, CDCl3) 138.7, 136.3, 133.3, 131.7, 123.0, 119.8, 22.4; m/z(EI) 284 (100%, [M(35Cl)]+); 
286 (58%,  [M(37Cl)]+); HRMS, found 281.8437 (C7H5 35Cl79Br2 requires 281.8446). 
Synthesis of 1,5-dibromo-2-chloro-4-(dibromomethyl)benzene (78). 
 
A solution of 4-bromo-5-chlorotoluene (1.0 g, 3.5 mmol), NBS (1.3 g, 11.0 mmol) and AIBN 
(5.0 mg, 0.01 mmol) in CH2Cl2 (30 mL) was irradiated with a tungsten lamp (Nikko Electron 
Co., Ltd., RF-110 V/500 WH) without external cooling while stirring for 4 hours. Then, 
succinimide was removed by filtration and aqueous sodium hydrogen sulphite was added to 
the filtrate. The organic layer was extracted with CH2Cl2 and dried over MgSO4. The solvent 
was removed under vacuum to provide the oily crude product, which was purified by flash 
column chromatography eluting 0→5% AcOEt/ 40-60 petroleum ether to give a clear waxy 
product (0.9 g, 71%) mp 54 - 58 °C; Vmax (solid /cm-1) 3075, 3013, 1448, 1339, 1045, 888, 640 
; δH (400 MHz, CDCl3) 8.10 (s, 1H), 7.81 (s, 1H), 6.94 (s, 1H); δC (101 MHz, CDCl3) 141.0, 136.6, 
135.1, 132.2, 124.7, 117.6, 37.4; m/z(EI) 440 (5%, [M(35Cl(79Br3)81Br)]+); 442 (10%,  
[M(35Cl(79Br2)(81Br2)]+); 363 (100%, [M(35Cl79Br(81Br2)]+); HRMS, found 437.6673 




Synthesis of 2,4-dibromo-5-chlorobenzaldehyde (80). 
 
A solution of 1,5-dibromo-2-chloro-4-(dibromomethyl)benzene (2.2 g, 5.0 mmol) in DMSO 
(100 mL) and water (15 mL) was heated to 120 °C and stirred overnight. The reaction mixture 
was poured into water (100 mL) and extracted with ethyl acetate (3 × 20 mL). The extract was 
washed with water (2 × 20 mL), brine and then was dried over MgSO4. The solvent was 
removed under reduced pressure, and the crude product purified by recrystallization from 
chloroform/ petroleum ether to afford the title compound as a colourless solid (1.3 g, 85%) 
Mp 110 - 112 °C; Vmax (solid /cm-1) 3077, 2879, 1680, 1561; δH (400 MHz, CDCl3)  10.25 (s, 1H), 
7.99 (s, 2H); δC (101 MHz, CDCl3) 189.5, 138.1, 135.3, 133.3, 130.6, 129.9, 124.2; m/z (EI) 302 
(10%, [M(35Cl81Br81Br)]+), 300 (47%, [M(35Cl(81Br2)]+); 298 (64%, [M(35Cl79Br81Br)]+), 296 (30%, 
[M(35Cl(79Br2)]+); HRMS, found 295.8251 ([C7H3O(35Cl(79Br2)] requires 295.8239). 
Synthesis of 2,4-dibromo-5-chlorobenzoic acid (81).30 
 
Oxone (4. 0 g, 26.4 mmol) was added to a solution of  2,4-dibromo-5-chlorobenzaldehyde (2.0 
g, 6.6 mmol) in DMF (20 mL) in one portion and the mixture was stirred for 48 h. 1 N HCl was 
added to dissolve the salts formed and the product was extracted with ethyl acetate. The 
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organic extracts were washed with brine, dried over anhydrous sodium sulfate and the 
solvent was removed under reduced pressure to afford the crude product. Recrystallization 
of the crude material in toluene afforded the title product (1.0 g, 52%) Mp 110 °C; δH (400 
MHz, DMSO-d6) 13.85 (s, 1H), 7.99 (s, 1H), 8.21 (s, 1H); δC (101 MHz, DMSO-d6) 138.7, 136.2, 
133.2, 131.6, 123.0, 119.8, 22.4. 
Synthesis of 2-amino-4-bromo-5-chlorobenzoic acid (82).31 
 
Copper oxide (228 mg, 1.6 mmol) was added to a solution of 4-bromo-5-chlorobenzoic acid 
(5.7 g, 18.0 mmol) in ammonium hydroxide (400 mL) and ethyl acetate (240 mL). The reaction 
was heated at reflux for 5 hours. EDTA (23.0 g, 79.0 mmol) was then added and the reaction 
was stirred overnight. 1 M HCl added to the solution until pH ~ 3 and the organic layer was 
extracted with ethyl acetate. The combined organic layers were washed with brine and dried 
over MgSO4. The solvent was removed under reduced pressure and, the resulting brown solid 
was recrystallized in toluene to yield the title compound as a cream solid (3.6 g, 68%) Mp 112 
°C. δH (400 MHz, DMSO-d6) 7.75 (s, 1H), 7.15 (s, 1H); δC (101 MHz, DMSO-d6) 168.3, 151.1, 
132.1, 127.3, 121.0, 117.8, 110.8; m/z(ESI) 253 (30%, [M(37Cl79Br)]+); 251 (100%, [M(35Cl 
79Br)]+); HRMS, found 249.9272 (C7H6NO35Cl79Br requires 249.9270). 





A mixture of 2-amino-4-bromo-5-chlorobenzoic acid (3.6 g, 14.0 mmol) in formamide (64.0 g, 
1.4 mol) and acetic acid (8.6 g, 14.0 mmol) was heated at 200 °C for 1 hour. The reaction 
mixture was cooled and ice water was added. The mixture was stirred for a further 30 mins 
at 0 °C to allow the product to precipitate from solution. The brown precipitate was filtered, 
washed with water and dried under vacuum to yield the product, which was purified by 
recrystallization from ethanol (2.2 g, 60%) Mp 270 °C (decomp.). δH (400 MHz, DMSO-d6) 
12.56 (s, 1H), 8.20 (s, 1H), 8.17 (s, 1H), 8.10 (s, 1H); δC (101 MHz, DMSO-d6) 159.8, 148.5, 
147.6, 132.6, 131.6, 128.4, 127.1, 123.5; m/z(ESI) 262 (20%, [M(37Cl 81Br)]+); 260 (100%, 
[M(35Cl 81Br)]+);  258 (70%,  [M(35Cl79Br)]+); HRMS, found 258.9282 (C8H5N2O35Cl79Br requires 
258.9274). 
12.3 SYNTHESIS TOWARDS FEBRIFUGINE ANALOGUES 
 
Synthesis of tert-butoxycarbonyl piperidine-2, 3-diyl diacetate (88).33 
 
To a solution of N-Boc-3,4-dihydro-2H-pyridine (1.0 g, 5.4 mmol) in acetone (50 mL) and 
water (5 mL)  were added two crystals of osmium tetraoxide. The reaction was then stirred at 
room temperature and monitored by TLC analysis. After completion, the mixture was cooled 
and quenched with a saturated solution of sodium metabisulfite (10 mL). Water (10 mL) was 
added and the product was extracted with diethyl ether (3 x 10 mL). The combined organic 
layers were washed with brine and dried over MgSO4. The mixture was filtered and 
concentrated under reduced pressure to give a white solid. The solid was immediately 
dissolved in CHCl3 and reacted with acetic anhydride (2.6 mL, 27 mmol), triethylamine (3.8 
mL, 27 mmol) and DMAP (66 mg, 0.5 mmol). After stirring for one hour the mixture was 
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diluted with water (10 mL) and extracted with CH2Cl2 (2 x 20 mL). The organic layers were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure to afford a 
yellow oil (1.21 g, 73%); δH (400 MHz, CDCl3),  6.82 (d, 1H, J = 6.5 Hz), 4.90 - 4.76 (m, 1H), 3.89 
- 3.83 (m, 2H),  3.10 - 3.04 (m, 2H), 2.94 - 2.86 (m, 2H ), 2.07 (s, 3H), 1.98 (s, 3H), 1.41 (s, 9H); 
δC (101 MHz, CDCl3) 169.2, 166.3, 153.9, 81.1, 80.9, 69.5, 45.0, 28.2, 28.0, 23.7, 22.9, 22.0, 
20.7, 20.3; m/z (ESI) 324(100%, [M(Na)]+); HRMS, found 324.1431 (C14H23N6Na requires 
324.1423). 
 
Synthesis of 3-(2-oxopropyl) quinazolin-4(3H)-one (84).10 
 
NaH 60% dispersion in mineral oil; (130 mg, 5.4 mmol) was added to a solution of 4-
hydroxyquinazoline (500 mg, 3.4 mmol) in DMF (20 mL). The reaction was then cooled to 0 oC 
and stirred for 30 min. Chloroacetone (0.5 mL, 6.8 mmol) was added dropwise and the 
reaction mixture was stirred at room temperature for 24 hours. Saturated NH4Cl was added 
and the product was extracted with ethyl acetate (2 x 20 mL). The organic layers were 
combined, washed with brine and dried over MgSO4. The organic solvent was removed under 
reduced pressure to afford the title a colourless solid (0.65 g, 93%); δH (400 MHz, CDCl3)  8.29 
(d, 1H, J = 8.0 Hz), 7.91 (s, 1H), 7.84 - 7.72 (m, 2H), 7.53 (t, 1H, J = 7.0 Hz), 4.78 (s, 2H), 2.39 (s, 
3H); δC (101 MHz, CDCl3) 200.0, 160.8, 148.1, 146.2, 134.5, 127.6, 127.4, 126.7, 121.8, 54.6, 
29.6. 




 Hünigs base (100 mg, 1.0 mmol) was added to a solution of 3-(2-oxopropyl) quinazolin-4(3H)-
one (100 mg, 0.5 mmol) dissolved in CH2Cl2 (5 mL). Trimethylsilyl trifluoromethane sulfonate 
(TMSOTf) (200 mg, 10.0 mmol) was then added dropwise. The mixture was stirred for 2 h, 
before it was added to a diethyl ether (10 mL)/ Water (10 mL) mixture. The organic layer was 
extracted with diethyl ether (2 × 10 mL); washed with sodium bicarbonate, brine and dried 
over Na2SO4. The solvent was removed under vacuum to afford the silyl enol ether as yellow 
oil (77. 0 mg, 66%). Without further purification the silyl enol ether was dissolved in CH2Cl2 
(5mL) with the tert-butoxycarbonyl piperidine-2, 3-diyl diacetate (200 mg, 0.5 mmol) and the 
mixture was cooled to -78 °C. The TMSOTf (11 mg, 0.5 mmol) was introduced and the reaction 
was stirred overnight. The reaction was quenched with NH4Cl (aq), extracted with CH2Cl2 and 
dried over MgSO4. The solvent was then removed under vacuum to afford the crude product, 
which was purified via flash column chromatography (CH2Cl2 : MeOH, 8 : 2) to give the title 
compound as a yellow oil (65 mg, 33%). Vmax ( solid /cm-1 ) 3088, 2671, 1766, 1713, 1671, 1612, 
1239, 1160, 1029, 912;  δH (400 MHz, CDCl3)  8.25 (d, 1H, J = 8.0 Hz), 7.95 (s, 1H), 7.74 - 7.70 
(m, 2H), 7.50 (t, 1H, J = 8.3 Hz),  4.92 (d, 1H, J = 13.0 Hz), 4.76 (d, 1H, J = 13.0 Hz), 4.56 - 4.50 
(m, 1H), 3.15 - 3.10 (m, 2H), 2.90 (dd, 2H, J = 4.0 Hz and J = 2.0 Hz), 2.75 - 2.70 (m, 1H), 2.65 - 
2.63 (m, 1H), 2.10 (s, 3H), 1.75 - 1.70 (m, 2H), 1.60 - 1.55 (m, 2H), 1.40 - 1.35 (m, 2H); δC (101 
MHz, CDCl3) 201.9, 170.4, 160.9, 148.2, 146.4, 134.5, 127.6, 127.4, 126.6, 121.7, 118.6, 72.5, 
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55.9, 54.6, 46.7, 45.2, 29.8, 24.4; m/z (ESI) 344 (100%, [M]+); HRMS, found 344.1604 
(C18H22N3O4 requires 344.1610). 
 91 afforded as a Clear oil (19 mg, 11%). Vmax ( solid /cm-1 ) 3090, 2924, 1766, 1713, 1672, 1610, 
1243,1155, 1029, 910; δH (400 MHz, CDCl3)  8.30 (d, 1H, J = 7.0 Hz), 7.95 (s, 1H), 7.75 - 7.71 
(m, 2H), 7.53 (t, 1H, J = 7.5 Hz), 4.95 -  4.92 (m, 1H),  4.88 (d, 1H, J = 4.0 Hz), 4.76 (d, 1H, J = 
4.0 Hz), 3.40 - 3.35 (m, 2H), 3.15 - 3.10 (m, 2H), 2.80 - 2.70 (m, 2H), 2.20 (s, 3H), 2.00 - 1.95 
(m, 2H), 1.70 - 1.65 (m, 2H); δC (101 MHz, CDCl3) 201.8, 170.4, 161.2, 147.3, 145.0, 134.5, 
128.0, 127.0, 126.6, 121.7, 118.6, 72.5, 56.2, 54.3, 46.3, 44.9, 30.8, 25.5; m/z (ESI) 344 (100%, 
[M]+); HRMS, found 344.1003 (C18H22N3O4 requires 344.1610). 
 
Synthesis of 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane (107).34 
 
Boron trifluoride diethyl etherate (20 mg, 0.1 mmol) was added to a solution of 
epichlorohydrin (2.0 g, 22.0 mmol) in acetone (19 mL) at 0 °C. The reaction mixture was then 
stirred for 1 h allowing the mixture to reach room temperature. The reaction mixture was 
then heated to 40 °C and left to stir for 5 h. Removal of the solvent under reduced pressure 
gave the title product as a clear oil (3.3 g, 97%). δH (400 MHz, CDCl3) 4.35 - 4.25 (m, 1H), 4.10 
(dd, 1H, J = 6.0 Hz and J = 2.5 Hz), 3.86 (dd, 1H, J = 5.5 Hz and J = 2.5 Hz), 3.60 - 3.55 (m, 1H), 
3.45 - 3.40 (m, 1H); δC (101 MHz, CDCl3) 110.1, 75.3, 67.4, 44.5, 26.8, 25.2. 




A mixture of 4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane (3.3 g, 21.0 mmol) and potassium 
hydroxide (7.3 g, 131.0 mmol) was heated to reflux . The reaction was left to stir overnight 
and the product was distilled out of the crude mixture at 110 °C under reduced pressure to 
afford the title product as a clear oil (1.0 g, 44%). δH (400 MHz, CDCl3)  4.49 (s, 2H), 4.26 (s, 
1H), 3.83 (s, 1H), 1.44 (s, 6H); δC (101 MHz, CDCl3) 156.1, 111.8, 77.6, 66.3, 25.0. 
Synthesis of Ethyl 2-(2-oxopyrrolidin-1-yl) acetate (115).35 
 
To a suspension of sodium hydride (11.3 g, 0.5 mol) in dry toluene (150 mL), 2-pyrrolidine 
(20.0 g, 0.2 mol) was added. The mixture was stirred at reflux for 1 h and then cooled to room 
temperature. Tetra-n-butyl ammonium bromide (7.7 g, 0.2 mol) and ethyl chloroacetate (35.8 
g, 0.3 mol) were added and the mixture was stirred for a further 48 h at room temperature. 
The solvent was removed under reduced pressure and ether (20 mL) was added to the 
residue. The mixture was filtered and the solvent removed under vacuum. The product was 
purified by distillation under reduced pressure to provide the title compound as a colourless 
oil (20.5 g, 50%). δH (400 MHz, CDCl3) 4.19 (q, 2H, J = 7.5 Hz), 4.05 (s, 2H), 3.50 (t, 2H, J = 7.0 
Hz), 2.39 (t, 2H, J = 8.0 Hz), 2.08 - 2.02 (m, 2H), 1.28 (t, 3H, J = 7.5 Hz); δC (101 MHz, CDCl3) 
175.5, 168.6, 61.1, 47.4, 44.0, 30.2, 17.8, 14.0. 




A solution of ethyl 2-(2-oxopyrrolidin-1-yl) acetate (20.4 g, 0.1 mol) in aqueous 5 M HCl (100 
mL) was heated at reflux for 48 h. The mixture was then cooled and concentrated. The residue 
was dissolved in methanol (100 mL) and the solution then evaporated under reduced pressure 
to afford the product as a colourless gum (22.0 g, 93%). δH (400 MHz, D2O) 4.05 (s, 2H), 3.08 
- 3.02 (m, 2H,), 2.44 - 2.31 (m, 2H), 2.00 - 1.80 (m, 2H); δC (101 MHz, D2O) 179.1, 171.0, 46.7, 
38.6, 30.4, 21.9. 
Synthesis of methyl 4-((2-methoxy-2-oxoethyl) amino) butanoate hydrochloride (117).35 
 
Acetyl chloride (3.6 g, 46.0 mmol) was added to methanol (30 mL) and the solution was stirred 
for 15 min. The mixture was transferred to a flask containing the 4-((carboxymethyl) amino) 
butanoic acid hydrochloride diacid (6.2 g, 32.0 mmol) and the resulting solution was heated 
at reflux overnight. After completion the mixture was allowed to reach room temperature 
and the solvent was removed under reduced pressure to afford the product as a yellow oil 
(6.3 g, 86%). δH (400 MHz, MeOD-d4) 5.48 (s, 1H), 4.10 (s, 2H), 3.87 (s, 3H), 3.71 (s, 3H), 3.15 - 
3.25 (m, 2H), 2.56 - 2.50 (m, 2H), 2.01-2.16 (m, 2H) ; δC (101 MHz, MeOD-d4) 168.8, 168.1, 




Synthesis of methyl 4-((tert-butoxycarbonyl) (2-methoxy-2-oxoethyl) amino) butanoate 
(118).35 
 
A solution of the methyl 4-((2-methoxy-2-oxoethyl) amino) butanoate hydrochloride diester 
(4.0 g, 17.0 mmol) in dichloromethane (10 mL) was added to a solution of the di-tert-butyl 
dicarbonate (5.8 g, 26.0 mmol) in CH2Cl2 (30 mL) and the mixture was allowed to stir for 10 
mins. Triethylamine (5.4 g, 53.0 mmol) was then added and the mixture was allowed to stir 
overnight. After completion the mixture was diluted with water (20 mL) and extracted with 
CH2Cl2 (2 ×20 mL). The organic layers were combined and washed with brine, then dried over 
MgSO4.  The solvent was removed under reduced pressure to afford the crude product, which 
was purified via flash column chromatography (60 / 40, Pet.ether/ EtOAc) to afford the 
product as a yellow oil (2.0 g, 40 %). δH (400 MHz, CDCl3) 3.70 (s, 2H) , 3.52 (s, 3H), 3.46 (s, 
3H), 3.13 (t, 2H, J = 6.8 Hz), 2.15 (t, 2H, J = 7.3 Hz), 1.68 - 1.55 (m, 2H), 1.23 (s, 9H); δC (101 
MHz CDCl3,) 173.6, 170.4, 155.7, 79.8, 51.3, 50.9, 47.5, 39.9, 30.8, 27.9, 23.4. 
 
Synthesis of 1-tert-butyl 2 methyl 3-oxopiperidine-1,2-dicarboxylate (108).35 
 
To a solution of the methyl 4-((tert-butoxycarbonyl) (2-methoxy-2-oxoethyl) amino) 
butanoate (2.0 g, 7.0 mmol) in toluene (30 mL) cooled to 0 °C, potassium tert-butoxide (3.2 g, 
28.0 mmol) was added in one portion. The mixture was stirred for 1 h and quenched with 
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acetic acid (10 mL), the resulting mixture was then extracted with diethyl ether (2 ×20 mL). 
The combined organic extracts were washed with 1 N HCl, water, brine and dried over MgSO4. 
The solvent was removed under reduced pressure to afford the crude product which was 
purified via flash column chromatography (60 / 40, Pet. ether/ EtOAc) to give the title 
compound as a yellow oil (0.6 g, 31%). δH (400 MHz, CDCl3) 11.12 (s, 1H), 5.22 (s, 1H), 5.06 (s, 
1H), 4.10 - 3.86 (m, 1H), 3.79 (s, 3H), 3.45 - 3.28 (m, 1H), 2.60 - 2.42 (m, 1.3H), 2.41 (t, 0.7H, J 
= 7.2 Hz), 2.08 - 1.95 (m, 1.3H), 1.90 - 1.81 (m, 0.7H), 1.49 (s, 3H), 1.44 (s, 6H); δC (101 MHz, 
CDCl3) 200.0, 175.0, 170.5, 165.5, 155.0, 81.2, 66.9, 65.5, 53.0, 41.4, 40.4, 37.8, 28.1, 26.5, 
22.7, 22.2 (Complexity of the NMR is due to rotamers and tautomers). 
Regioisomer afforded as a clear oil (0.2 g, 10%), δH (400 MHz, CDCl3) 1.45 ( s, 9H), 2.29 (m, 
2H), 3.45 ( t, 2H, J = 5.5 Hz) , 3.75 (s, 3H), 4.01 (s, 2H), 11.95 (s, 1H) ; δC (101 MHz, CDCl3) 172.0, 
167.0, 154.5, 98.5, 96.8, 79.4, 51.6, 45.5, 41.2, 39.9, 28.3, 21.9. 
 
Synthesis of methyl 3-hydroxypicolinate (112).  
 
Sulfuric acid (14.1 g, 144.0 mmol) was added to a solution of 3-hydroxypyridine-2-carboxylic 
acid (2.0 g, 14. 4 mmol) in methanol (125 mL). The mixture was heated to reflux overnight 
and quenched with NaHCO3. The reaction mixture was extracted with diethyl ether and the 
combined organic layers were washed with water, brine and dried over MgSO4. The solvent 
was removed under reduced pressure to yield the title product as a colourless oil (1.1 g, 49%); 
δH (400 MHz, CDCl3) 10.50 (s, 1H),  8.15 (d, 2H, J = 1.3 Hz), 7.50 (t, 1H, J = 2.8 Hz), 7.45 (d, 1H, 
J = 1.3 Hz), 3.88 (s, 3H); δC (101 MHz, CDCl3) 168.1, 155.9, 141.1, 133.6, 129.2, 125.9, 52.83. 
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Synthesis of methyl 3-hydroxypiperidine-2-carboxylate (113). 36 
 
A solution of methyl 3-hydroxypicolinate (1.0 g, 7.0 mmol) in ethanol (140 mL) was introduced 
into a continuous flow hydrogenation reactor H-cube. The reaction mixture was subjected to 
80 bars of hydrogen and was heated to 100 °C for 4 h. After completion the reacted solution 
was cooled down and the solvent was removed under reduced pressure to afford the title 
product as yellow oil (1.1 g, 97%). δH (400 MHz, CDCl3) 3.89 - 3.84 (m, 1H), 3.60 (s, 3H), 3.40 
(d, 1H, J = 2.5 Hz), 2.94 - 2.89 (m, 2H), 2.48 - 2.40 (m, 2H), 1.65 - 1.57 (m, 2H); δC (101 MHz, 
CDCl3) 172.1, 68.6, 62.8, 51.9, 45.0, 31.1, 19.9. 
Synthesis of 1-tert-butyl 2-methyl 3-hydroxypiperidine-1,2-dicarboxylate (114).35 
 
Methyl 3-hydroxypiperidine 2-carboxylate (1.1 g, 6.8 mmol) was added to a solution of Boc 
anhydride (1.9 g, 8.8 mmol) in DCM. Triethylamine (0.9 g, 8.8 mmol) was added and the 
resulting solution was stirred overnight. The mixture was diluted with water and extracted 
with DCM. The combined organic layers were washed with water, brine and dried over 
MgSO4. The solvent was removed under reduced pressure to afford the oily product (1.0 g, 
56%); δH (400 MHz, CDCl3) 5.12 - 5.04 (m, 1H) , 4.96 - 4.92 (m, 1H), 4.05 - 3.95 (m, 1H), 3.80 
(s, 3H), 2.80 - 2.74 (m, 1H), 2.66 - 2.54 (m, 2H), 2.00 - 1.90 (m, 2H), 1.40 (s, 9H); δC (101 MHz, 
CDCl3) 172.5, 155.3, 80.5, 69.0, 61.4, 52.2, 41.4, 30.0, 28.2, 23.3. 




4-hydroxyquinazoline (1.0 g, 7.0 mmol) was added to a solution of NaH 60% dispersion in 
mineral oil (0.3 g, 10.0 mmol) in DMF (50 mL). The mixture was cooled to 0 °C and left to stir 
for 30 mins before, 3-chloro-2-chloro-methyl propene (5.1 g, 41.0 mmol) was added 
dropwise. The mixture was heated to 50 °C for 4 h. After cooling to room temperature the 
reaction was quenched with NH4Cl (aq) (20 mL) and the product extracted with ethyl acetate 
(2 × 30 mL). The combined organic layers were washed with aqueous LiCl solution (5% 
mass/volume), brine and dried over MgSO4. The solvent was removed under vacuum to afford 
the crude product, which was purified by recrystallization in chloroform/ petroleum ether (1/ 
9) to give the title product (0.9 g, 60%). Vmax ( solid /cm-1 ) 3064, 2963 1661, 1606, 990, 800; 
δH (400 MHz, CDCl3) 8.34 (d, 1H,  J = 6.0 Hz), 8.09 (s, 1H), 7.85 - 7.75 (m, 2H), 7.60 - 7.50 (m, 
1H), 5.41 (s, 1H), 5.15 (s, 1H), 4.78 (s, 2H), 4.15 (s, 2H); δC (101 MHz, CDCl3) 160.7, 147.9, 146.4, 
139.6, 134.3, 127.4, 127.3, 126.6, 121.9, 117.8, 47.7, 45.7; m/z (ESI) 235 (100%, [M (Cl 35]+); 
HRMS, found 235.0647 (C12H12N2O35Cl requires 235.0638).  
 128 formed as a colourless solid (54.0 mg, 6%) Mp 198 - 199 °C. Vmax ( solid /cm-1 ) 3064, 2964, 
1661, 1605, 989, 768;   δH (400 MHz, CDCl3) 8.32 (d, 2H, J = 6.0 Hz), 8.11 (s, 2H), 7.75 (m, 4H), 
7.55 (m, 2H), 5.17 (s, 2H), 4.72 (s, 4H); δC (101 MHz, CDCl3) 160.9, 148.0, 146.1, 138.9, 134.5, 
127.6, 127.5, 126.8, 121.9, 116.5, 48.3; m/z (ESI) 345 (100%, [M]+); HRMS, found 345.1353 
(C20H17N4O2 requires 345.1352). 
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Synthesis of 3-(2-(iodomethyl) allyl) quinazolin-4 (3H)-one (130). 
 
Sodium iodide (0.2 g, 1.5 mmol) was added to a solution of 3-(2-(chloromethyl) allyl) 
quinazoline-4(3H)-one (0.3 g, 1.3 mmol) in acetone (30 mL). The mixture was heated at reflux 
for 3 h. After completion (as judged by TLC analysis) the mixture was cooled to room 
temperature, quenched with water (10 mL) and extracted with diethyl ether (2 × 20 mL). The 
combined organic layers were washed with dilute sodium bisulfite, water, brine and dried 
over MgSO4. The solvent was removed under reduced pressure to afford the product as a 
yellow oil (0.3 g, 69%). Vmax (solid)/cm-1) 3063, 2921, 1661, 1605, 989, 508; δH (400 MHz, CDCl3) 
8.32 (d, 1H, J = 6.0 Hz), 8.09 (s, 1H), 7.83 - 7.73 (m, 2H), 7.57 - 7.51 (m, 1H), 5.48 (s, 1H), 5.03 
(s, 1H), 4.81 (s, 2H), 3.97 (s, 2H); δC (101 MHz, CDCl3) 161.0, 148.0, 146.2, 140.9, 134.4, 127.6, 
127.5, 126.8, 122.0, 116.6, 48.7, 5.6. m/z (ES) 327 (100%, [M(127I)]+); HRMS, found 327.0005 
([C12H12N2O127I] requires 326.9994). 
Synthesis of 2-((4-oxoquinazolin-3 (4H)-yl) methyl) allyl acetate (131).37 
 
A solution of 3-(2-(chloromethyl) allyl) quinazoline-4(3H)-one (0.3 g, 1.3 mmol) and sodium 
acetate (0.1 g, 1.6 mmol) in DMF (30 mL) was heated at 85 °C. The reaction mixture was 
monitored by thin layered chromatography until completion. Water (20 mL) was added and 
the mixture was extracted with ethyl acetate (2 × 20 mL). The combined organic layers were 
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washed with aqueous LiCl (5% mass/volume), Brine and then dried over MgSO4. The solvent 
was removed under vacuum to afford the oily product (0.23 g, 70%). δH (400 MHz, CDCl3) 8.32 
(d, 1H, J = 6.0 Hz), 8.09 (s, 1H), 7.82 - 7.73 (m, 2H), 7.58 - 7.51 (m, 1H), 5.48 (s, 1H), 5.20 (s, 
1H), 4.79 (s, 2H), 4.76 (s, 2H), 2.03 (s, 3H); δC (101 MHz, CDCl3) 170.3, 160.8, 147.9, 146.2, 
138.5, 134.4, 127.5, 127.4, 126.8, 121.9, 117.3, 64.4, 47.8, 20.7. 
Synthesis of 3-bromo-2,2-bis (bromomethyl) propan-1-ol (123).37 
 
A mixture of pentaerythritol (6.0 g, 44.0 mmol) in glacial acetic acid (29.6 g, 49.0 mmol) and 
48% queous HBr (8.3 g, 0.1 mol) was refluxed for 24 h. Then 48% aqueous HBr (35.2 g, 0.4 
mol) and concentrated sulphuric acid (20.0 g, 0.2 mol) were added. The resulting solution was 
refluxed a further 24 h. After cooling to an ambient temperature, the mixture was extracted 
with dichloromethane. The extracts were combined, washed with water, brine and dried over 
anhydrous potassium carbonate.  The solvent was removed under reduced pressure to afford 
the crude product, which in turn was subjected to flash column chromatography (Et2O: 
Petroleum ether 40/60 (4:6)) to provide the colourless product (7.58 g, 53%); δH (400 MHz, 
CDCl3) 3.75(s, 2H), 3.55 (s, 6H); δC (101 MHz, CDCl3) 62.3, 44.2, 34.4. 
Synthesis of 3,3-bis (bromomethyl) oxetane (121). 
 
To a solution of sodium hydride (0.1 g, 5.0 mmol) in dry diethyl ether (5 mL) 3-bromo-2,2-bis 
(bromomethyl) propan-1-ol (1.0 g, 3.0 mmol) was added. The reaction mixture was left to stir 
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overnight and the unreacted sodium hydride was quenched by the addition of methanol. The 
mixture was filtered and the solvent was removed under reduced pressure to afford the oily 
crude product. The crude product was subjected to flash column chromatography (Et2O: 
Petroleum ether 40/60 (1 : 9)) to afford the title product as a clear oil (0.2 g, 30%); δH (400 
MHz, CDCl3)   3.85 (s, 4H), 4.42 (s, 4H); δC (101 MHz, CDCl3) 71.2, 44.9, 37.0.  
 Synthesis of benzyl 2,3-dihydroxypiperidine-1-carboxyalte (138). 38 
 
To a solution of N-Boc-3,4-dihydro-2H-pyridine (1.0 g, 5.4 mmol) in acetone (50 mL) and 
water (5 mL) a few crystals of osmium tetroxide were added. The reaction was stirred at room 
temperature and monitored by TLC analysis. After completion, the mixture was cooled and 
quenched with a saturated solution of sodium metabisulfite (10 mL). Water (10 mL) was 
added and the product was extracted with ethyl acetate (3 x 10 mL). The combined organic 
layers were washed with brine and dried over anhydrous MgSO4. The mixture was filtered 
and concentrated under reduced pressure to give the crude product. The crude residue was 
purified via flash column chromatography eluting with petroleum ether : EtOAc (6 : 4) to give 
the title product as a yellow oil (922 mg, 68%); δH (400 MHz, CDCl3) 7.38 - 7.34 (m, 5H), 5.75 
(d, 1H, J = 3.5 Hz), 5.13 (s, 2H), 3.90 - 3.82 (m, 1H), 3.64 - 3.56 (m, 1H), 3.10 (dt, 1H, J = 12.0, 
2.0 Hz), 1.86 - 1.78 (m, 1H), 1.74 - 1.66 (m, 2H), 1.56 - 1.46 (m, 1H); δC (101 MHz, CDCl3) 156.0, 
136.1, 128.5, 128.2, 127.9, 76.5, 69.0, 67.5, 36.1, 26.6, 23.5. 





To a solution of benzyl 2,3-dihydroxypiperidine-1-carboxyalte (200 mg, 0.8 mmol) and 
pyridine (251 mg, 3.2 mmol) in dichloromethane (6 mL) at 0 °C, triphosgene (259 mg, 0.8 
mmol) was added. The mixture was monitored by TLC analysis whilst maintaining the 
temperature. After completion, diethyl ether (10 mL) was added and the crude mixture 
including the salts was washed with a CuSO4 (satd.) solution. The layers were separated and 
the organic layer was washed with brine, dried over anhydrous MgSO4 and removed under 
reduced pressure to afford the title product as a clear oil (141 mg, 64%). Vmax (solid /cm-1) 
3661, 2956, 2197, 1794, 1704, 695; δH (400 MHz, CDCl3) 7.44 - 7.32 (m, 5H), 6.66 (d, 1H, J = 
5.0 Hz), 5.23 - 5.15 (m, 2H), 4.95 - 4.88 (m, 1H), 3.95 - 3.70 (m, 2H), 3.45 - 3.30 (m, 1H), 2.05 - 
1.99 (m, 1H), 1.89 - 1.77 (m, 2H); δC (101 MHz, CDCl3) 157.5, 156.0, 136.3, 128.3, 128.2, 128.1, 
90.8, 74.6, 67.4, 40.7, 23.4, 22.6; m/z (ESI) 300 (100%, [M(Na)]+); HRMS, found 300.0846 
([C14H15NO5Na] requires 300.0842). 
Synthesis of benzyl 2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-b]pyridine-4(3aH)-carboxylate 
(136). 
 
To a solution of benzyl 2,3-dihydroxypiperidine-1-carboxyalte (303 mg, 1.2 mmol) in acetone 
(6 mL), FeCl3 (98 mg, 0.6 mmol) was added. The reaction was stirred at room temperature for 
16 h. The mixture was then diluted with water (20 mL) and product extracted with ethyl 
acetate (2 x 20 mL). The combined organic layers were washed with brine, dried over 
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anhydrous MgSO4 and the solvent removed under reduced pressure to afford the crude 
product. The crude residue was purified via flash column chromatography eluting with 
petroleum ether : EtOAc (6 : 4) to give the title product (188 mg, 54%) Mp 166 - 167 °C. Vmax 
(solid /cm-1) 3661, 2941, 2159, 1976, 1702, 1076, 694; δH (400 MHz, CDCl3) 7.45 - 7.30 (m, 
5H), 5.96 (d, 1H, J = 8.0 Hz), 5.26 - 5.10 (m, 2H), 4.12 (q, 1H, J = 6.0 Hz), 3.09 - 3.80 (m, 2H), 
3.70 - 3.65 (m, 2H), 2.53 - 2.48 (m, 2H), 2.12 - 2.19 (m, 2H), 2.07 - 2.00 (m, 2H), 1.45 (s, 6H); 
δC (101 MHz, CDCl3) 156.0, 136.5, 128.6, 128.5, 128.2, 128.1, 128.0, 111.8, 89.9, 72.5, 68.0, 
42.5, 23.5, 23.3, 22.3, 21.5; m/z (ESI) 292 (100%, [M]+); HRMS, found 292.1543 ([C16H21NO4] 
requires 292.1543). 
Synthesis of 1-((benzyloxy)carbonyl) piperidine-2,3-diacetate (137). 38 
 
To a solution of benzyl 2,3-dihydroxypiperidine-1-carboxyalte (400 mg, 1.5 mmol) in CH2Cl2 
(10 mL), acetic anhydride (325 mg, 3.2 mmol), triethylamine (321 mg, 3.2 mmol) and DMAP 
(18 mg, 0.1 mmol) were added. The mixture was left to stir for 1 h then diluted with water 
(10 mL). The product was extracted with CH2Cl2 (2 x 20 mL) and the combined organic layers 
were dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to 
afford the crude product. The crude residue was purified via flash column chromatography 
eluting with petroleum ether : EtOAc (6 : 4) to give the title product (432 mg, 86%); δH (400 
MHz, CDCl3) 7.40 - 7.28 (m, 5H), 7.00 (d, 1H, J = 4.0 Hz), 5.21 (d, 1H, J = 15.0 Hz), 5.12 (d, 1H, 
J = 15.0 Hz), 4.92 - 4.85 (m, 1H), 4.00 - 3.95 (m, 1H), 3.01 (t, 1H, J = 14.0 Hz), 2.08 (s, 3H), 2.00 
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(s, 3H), 1.88 - 1.64 (m, 4H); δC (101 MHz, CDCl3) 170.0, 169.2, 154.7, 136.0, 128.5, 128.1, 127.9, 
75.3, 69.5, 67.7, 39.2, 23.8, 23.0, 20.8, 20.8. 
Synthesis of benzyl 7-oxa-2-azabicyclo[4.1.0] heptane-2-carboxylate (132). 
 
Oxone monopersulfate (45.0 g, 147.0 mmol) was added portion wise to a solution of sodium 
bicarbonate (60.0 g, 720.0 mmol) in water (300 mL), and the mixture was allowed to stir for 
10 mins. To this solution was added acetone (240 mL) and benzyl 3,4-dihydropyridine-1(2H)-
carboxylate (4.0 g, 18.0 mmol). The mixture was allowed to stir for 16 h at room temperature. 
After completion, water (100 mL) was added and the organic layer extracted with ethyl 
acetate (2 x 50 mL). The combined organic layers were dried over anhydrous MgSO4 and the 
solvent removed under reduced pressure to afford the crude product, which was purified by 
flash column chromatography eluting with cyclohexane : EtOAc (2 : 8) to afford the title 
product as a clear oil (3.5 g, 60%) and as a 1 : 1 mixture of rotamers. Vmax (solid /cm-1) 3375, 
2947, 1673, 1255, 987;  δH (400 MHz, CDCl3) 7.37 - 7.20 (s, 5H), 5.75 (s, 0.5H), 5.60 (s, 0.5H), 
5.15 (s, 2H), 4.17 - 4.11 (m, 0.5H), 3.95 - 3.85 (m, 2H), 3.65 - 3.55 (m, 0.5H), 3.24 - 3.16 (m, 
1H), 3.12 - 3.04 (m, 1H), 1.57 - 1.40 (m, 2H); δC (101 MHz, CDCl3) 157.0, 136.2, 128.5, 128.2, 
128.1, 127.9, 127.8, 67.5, 67.0, 45.7, 44.7, 22.5, 22.4; m/z (ESI) 234 (100%, [M]+); HRMS, found 
234.2614  ([C13H15NO3] requires 234.2613). 




To a solution of benzyl 7-oxa-2-azabicyclo[4.1.0]heptane-2-carboxylate (3.5 g, 149.0 mmol) 
and chlorotrimethylsilane (2.9 g, 179.0 mmol) in dichloromethane (40 mL) at -78 °C, BF3.OEt2 
(2.1 g, 149.0 mmol) was added. The reaction was allowed to stir overnight. NaHCO3 (aq) (20 
mL) was added and the reaction mixture was extracted with EtOAc (2 x 20 mL). The combined 
organic layers were dried over MgSO4 and the solvent was removed under reduced pressure 
to afford the crude oil which was purified by chromatography eluting with petroleum ether : 
EtOAc (4 : 6) to afford title product 133 as a clear oil (1.5 g, 31%) as a 1 : 1 mixture of rotamers. 
Vmax (solid /cm-1) 3444, 2938, 2516, 2159, 2028, 1670, 1424 ; δH (400 MHz, DMSO-d6) 7.42 - 
7.30 (m, 5H), 5.16 - 5.14 (m, 1H), 5.08 - 4.98 (m, 2H), 4.80 - 4.78 (m, 1H), 4.35 - 3.95 (m, 3H), 
3.90 - 3.85 (m, 1H), 3.65 - 3.55 (m, 1H), 2.97 - 2.82 (m, 1H), 2.35 - 2.25 (m, 2H), 1.80 - 1.70 (m, 
2H), 1.60 - 1.55 (m, 2H), 1.35 - 1.25 (m, 1H); δC (101 MHz, DMSO-d6) 155.9, 155.8, 142.4, 142.2, 
137.7, 137.4, 128.8, 128.2, 128.0, 127.6, 117.6, 117.3, 66.6, 66.3, 65.9, 65.4, 55.7, 55.4, 53.2, 
48.2, 47.9, 38.9, 38.6, 32.5, 26.0, 24.4, 24.1; m/z (ESI) 324 (100%, [M(35Cl2)]+); HRMS, found 
324.1374  ([C17H23NO335Cl2] requires 324.1366). 
134 clear oil (1.7 g, 35%) as a 1 : 1 mixture of rotamers. Vmax (solid /cm-1) 3444, 2938, 2516, 
2159, 2028, 1670, 1424; δH  (400 MHz, DMSO-d6) 7.40 - 7.29 (m, 5H), 5.12 - 4.99 (m, 4H), 4.45 
- 4.40 (m, 2H), 4.30 - 4.25 (m, 1H), 4.20 - 4.15 (m, 2H), 4.05 - 3.95 (m, 1H), 3.85 - 3.75 (m, 1H), 
3.65 - 3.55 (m, 1H), 2.86 - 2.74 (m, 2H), 1.66 - 1.62 (m, 2H), 1.42 - 1.30 (m, 1H); δC (101 MHz, 
DMSO-d6) 155.2, 155.1, 142.9, 142.8, 137.6, 137.1, 128.9, 128.5, 128.1, 127.7, 117.5, 117.1, 
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68.2, 67.8, 66.8, 66.4, 55.4, 54.4, 53.6, 48.2, 48.0, 37.8, 37.4, 27.7, 26.8, 24.6, 24.2; m/z (ESI) 
324 (100%, [M(35Cl2)]+); HRMS, found 324.1367  ([C17H23NO335Cl2] requires 324.1366). 
General Procedure for the Synthesis of Oxazolines. 
 
To the benzoic acid (1.0 equiv) in a round bottomed flask was added dichloromethane (0.2 
M) and the mixture cooled to 0 °C using an ice/H2O bath. Oxalyl chloride was then added (3.0 
equiv), followed by a few drops of DMF. The reaction mixture was warmed to room 
temperature and stirred for a period of 3 h. The reaction mixture was concentrated, re-
dissolved in dichloromethane (0.2 M) and cooled to 0 °C using an ice/H2O bath. Triethylamine 
(3.0 equiv) was added via syringe, followed by ethanolamine (3.0 equiv), and the reaction was 
warmed to room temperature and stirred for 16 h. The reaction mixture was then 
concentrated and the residue was purified by trituration with ethyl acetate or flash column 
chromatography on silica gel with petroleum ether (40/60)/ethyl acetate to afford the amide 
product which was used subsequently in oxazoline formation. 
To the amide substrate (1.0 equiv) in a round bottomed flask was added dichloromethane 
(0.6 M), trimethylamine (1.9 equiv), DMAP (0.2 equiv) and p-toluenesulfonyl chloride (1.7 
equiv). The reaction mixture was stirred for 16 h, quenched with water and the product 
extracted with dichloromethane. The combined organic layers were dried over MgSO4, 
filtered and the solvent was removed in vacuo. The residue was treated with methanol (0.5 
M) and sodium hydroxide pellets (3.0 equiv) for a period of 2 - 3 hours. The reaction mixture 
was then concentrated. The residue was dissolved in dichloromethane and water and the 
product extracted with dichloromethane. The combined organic layers were dried over 
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MgSO4, filtered and the solvent was removed in vacuo. Purification by flash column 
chromatography on silica gel afforded the desired oxazoline substrates.  
2-(3,4-Dichlorophenyl)-4,5-dihydrooxazole.  
 
3,4-Dichlorobenzoic acid (2.0 g, 10.5 mmol) was subjected to the general reaction conditions 
to  afford the corresponding amide (1.0 g, 44%). The corresponding oxazoline was then 
afforded as a colourless solid (623 mg, 63%) Mp 95 - 96 °C. Vmax (solid /cm-1) 3082, 2983, 1647, 
1241, 1071, 714; δH (400 MHz, CDCl3) 7.99 (d, 1H, J = 2.0 Hz), 7.73 (dd, 1H, J = 8.5, 2.0 Hz), 
7.44 (d, 1H, J = 8.5 Hz), 4.41 (t, 2H, J = 9.5 Hz), 4.03 (t, 2H, J = 9.5 Hz); δC (101 MHz, CDCl3) 
162.8, 135.6, 132.8, 130.5, 130.1, 127.8, 127.3, 68.0, 55.1; m/z (ESI) 215 (100%, [M(35Cl2)]+); 
HRMS, found 215.9977 ([C9H8NO35Cl2] requires 215.9983). 
2-(4-Bromo-3-fluorophenyl)-4,5-dihydrooxazole. 
 
4-Bromo-3-fluorobenzoic acid (2.0 g, 9.1 mmol) was subjected to the general reaction 
conditions to afford the corresponding amide (1.6 g, 70%). The corresponding oxazoline was 
then afforded as a colourless solid (1.5 g, 77%) Mp 95 - 96 °C. Vmax (solid /cm-1) 3078, 2938, 
1644, 1422, 951, 712; δH (400 MHz, MeOD-d4) 7.75 (m, 2H), 7.60 (dd, 1H, J = 6.0 Hz, 2.0 Hz), 
4.67 (t, 2H, J = 6.0 Hz), 4.10 (t, 2H, J = 6.0 Hz); δC (101 MHz, MeOD-d4) 163.5, 160.0 (d, J = 
250.0 Hz), 133.7, 129.4, 124.8, 115.0 (d, J = 28.0 Hz), 110.3 (d, J = 27.5 Hz), 68.8, 54.0; δF (376 
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MHz, MeOD-d4) - 108.2; m/z (ESI) 243 (100%, [M(79Br)]+); HRMS, found 243.9768 
([C9H779BrFNO] requires 243.9768). 
General Procedure for the C-H Amidation of Oxazoline Substrates. 
 
 Oxazoline substrate (1.2 equiv) was placed in a round bottomed flask equipped with a reflux 
condenser. Trifluoroacetamide (1.0 equiv), [RhCp*Cl2]2 (2.5 mol %), AgSbF6 (10 mol %) and 
PhI(OAc)2 (1.5 equiv) were all added sequentially and the resulting mixture dissolved in 
dichloromethane (0.1 M). The reaction was then heated at reflux for a period of 24 hours. 
After cooling to room temperature the solvent was removed in vacuo. The resulting residue 
was purified by flash column chromatography on silica gel eluting with dichloromethane or 




2-(3,4-Dichlorophenyl)-4,5-dihydrooxazole (617 mg, 2.8 mmol) and trifluoroacetamide (260 
mg, 2.3 mmol) were subjected to the general conditions affording a colourless solid (495 mg, 
64%) Mp 135 - 136 °C. Vmax (solid /cm-1) 3117, 2887, 1711, 1145; δH (400 MHz, CDCl3) 13.64 (s, 
1H), 8.85 (s, 1H), 7.94 (s, 1H), 4.46 (t, 2H, J = 9.5 Hz), 4.18 (t, 2H, J = 9.5 Hz); δC (101 MHz, 
CDCl3) 163.3, 155.8 (q, J = 38.5 Hz), 137.0, 136.6, 130.6, 128.2, 122.0, 115.8 (q, J = 288.5 Hz), 
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114.2, 67.1, 54.6; δF (376 MHz, CDCl3) - 76.0; m/z (ESI) 326 (100%, [M(35Cl2)]+); HRMS, found 
326.9931 ([C11H8N2O2F335Cl2] requires 326.9915). 
N-(5-Bromo-2-(4, 5-dihydrooxazol-2-yl)-4-fluorophenyl)-2, 2, 2-trifluoroacetamide. 
 
2-(4-Bromo-3-fluorophenyl)-4,5-dihydrooxazole (1.1 g, 4.6 mmol) and trifluoroacetamide 
(430 mg, 3.8 mmol) were subjected to the general conditions affording a colourless solid (690 
mg, 42%) Mp 115 - 116 °C. Vmax (solid /cm-1) 2889, 1750, 1639, 1577, 1524, 1449, 1122, 1138; 
δH (400 MHz, CDCl3) 11.92 (s, 1H), 7.60 - 7.52 (m, 2H), 4.48 (t, 2H, J = 10.0 Hz), 4.16 (t, 2H, J = 
10.0 Hz); δC (101 MHz, CDCl3) 163.0, 158.1 (d, J = 250.0 Hz), 156.2 (q, J = 25.0 Hz), 139.0, 125.7, 
120.9, 115.5 (d, J = 27.0 Hz), 114.3 (d, J = 26.5 Hz), 113.9 (q, J = 260.0 Hz), 68.8, 55.0 ; δF (376 
MHz, CDCl3) - 75.4, -108.5; m/z (ESI) 355 (100%, [M(79Br)]+); HRMS, found 355.9733 
([C11H7N2O2F479Br] requires 355.9711). 
General Procedure for the Cyclization to the Quinazoline Heterocycle. 
 
Trifluoroacetamide substrate (1.0 equiv) was dissolved in ethanol (0.1 M), NaOH pellets (20 
equiv) were added and the reaction mixture was allowed to stir at room temperature. The 
reaction was monitored by TLC analysis until complete conversion of the starting material was 
observed (typically 5 - 6 h); upon completion the solvent was removed in vacuo. The residue 
was dissolved in water and ethyl acetate, and transferred to a separating funnel. The layers 
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were partitioned, followed by further extraction of the aqueous layer with ethyl acetate. The 
combined organics were then washed with brine, followed by drying over MgSO4, filtered and 
the solvent removed in vacuo. The residue was then dissolved in ethanol (0.1 M) and 
formamidine acetate (3.0 equiv) was added, and the mixture heated at reflux for 1 hour.  After 
cooling to room temperature, the reaction mixture was dry loaded onto silica gel and purified 
by flash column chromatography eluting with dichloromethane and methanol to afford the 
quinazolinone products.  
2-((6, 7-Dichloroquinazolin-4-yl) amino) ethanol. 
 
N-(4,5-Dichloro-2-(4,5-dihydrooxazol-2-yl)phenyl)-2,2,2-trifluoroacetamide (490 mg, 1.5 
mmol), sodium hydroxide (1.2 g, 30.3 mmol) and formamidine acetate (470 mg, 4.5 mmol) 
were subjected to the general reaction conditions to afford the product as a colourless solid 
(283 mg, 73%) Mp 204 - 205 °C. Vmax (solid /cm-1) 3315, 3006, 2981, 1580, 1362, 1059, 913, 
873; δH (400 MHz, DMSO-d6) 8.66 (s, 1H), 8.52 (br, 1H), 8.48 (s, 1H), 7.93 (s, 1H), 4.82 (br, 1H), 
3.66 - 3.55 (m, 4H); δC (101 MHz, DMSO-d6) 158.6, 156.5, 148.6, 135.3, 128.7, 127.7, 124.9, 






N-(5-Bromo-2-(4,5-dihydrooxazol-2-yl)-4-fluorophenyl)-2,2,2-trifluoroacetamide (670 mg, 
1.9 mmol), sodium hydroxide (1.5 g, 3.8 mmol) and formamidine acetate (590 mg, 5.7 mmol) 
were subjected to the general reaction conditions to afford the product as a colourless solid 
(0.15 mg, 55%) Mp 210 - 211 °C. Vmax (solid /cm-1) 3316, 3004, 2989, 1584, 1365, 1059, 914, 
873; δH (400 MHz, MeOD-d4) 8.50 (s, 1H), 7.88 (d, 1H, J = 7.0 Hz), 7.73 - 7.60 (m, 1H), 3.86 - 
3.76 (m, 4H); δC (101 MHz, MeOD-d4) 159.0, 153.5, 153.3 (d, J = 260. 0 Hz), 148.8, 130.1, 119.3 
(d, J = 25.0 Hz), 112.6 (d, J = 25.0 Hz), 106.2, 57.9, 42.5; δF (376 MHz, MeOD-d4) - 108.8; m/z 
(ESI) 285 (100%, [M(79Br)]+); HRMS, found 285.9983 ([C10H979BrFN3O] requires 285.9986). 
General Procedure for the Hydrolysis to the Quinazolinone Heterocycle.  
 
Quinazolinone substrate (1.0 equiv) was suspended in aqueous 6 M HCl in a round bottomed 
flask equipped with reflux condenser, and heated to 100 - 105 °C. The reaction was then 
allowed to cool to room temperature, then cooled to 0 °C with an ice/water bath. The reaction 
mixture was basified to pH 11 with 35% aqueous ammonia solution, and allowed to stir for 
15 minutes. The resulting precipitate was filtered and washed with ice cold water to afford 





2-((6,7-Dichloroquinazolin-4-yl)amino)ethanol (181 mg, 0.7 mmol) was added to aqueous 6 
M HCl (5 mL) according to the general conditions for 2 h to afford the product as a colourless 
solid (132 mg, 88%) Mp > 250 °C. Vmax (solid /cm-1) 3047, 3012, 1665, 1611, 1444, 1254, 1122, 
910, 866; δH (400 MHz, DMSO-d6) 12.18 (s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 7.95 (s, 1H); δC (101 
MHz, DMSO-d6) 159.3, 148.3, 147.3, 137.1, 129.3, 128.9, 127.2, 122.7; m/z (ESI) 214 (100%, 
[M(35Cl2)]+); HRMS, found 214.9772 ([C8H435Cl2N2O] requires 214.9773). 
7-Bromo-6-fluoroquinazolin-4(3H)-one (157). 
 
2-((7-Bromo-6-fluoroquinazolin-4-yl)amino)ethanol (100 mg, 3.6 mmol) was added to 
aqueous 6 M HCl (2.5 mL) according to the general conditions for 2 h to afford the product as 
a colourless solid (50 mg, 50%) Mp > 250 °C. Vmax (solid /cm-1) 3316, 3004, 2989, 1584, 1365, 
1059, 914, 873; δH (400 MHz, DMSO-d6) 12.40 (s, 1H), 8.20 (s, 1H), 8.09 (d, 1H, J = 3.0 Hz), 7.93 
(d, 1H, J = 5.0 Hz); δC (101 MHz, DMSO-d6) 160.2, 157.8 (d, J = 260.0 Hz), 146.7, 146.6, 132.8, 
123.8, 116.5 (d, J = 24.0 Hz), 112.3 (d, J = 24.0 Hz); δF (376 MHz, DMSO-d6) - 109.2; m/z (ESI) 
285 (100%, [M(79Br)]+); HRMS, found 285.9983 ([C10H979BrFN3O] requires 285.9986). 




Potassium carbonate (1.5 equiv) was added to a suspension of quinazolinone (1.0 equiv) in 
MeCN (0.1 M) and the mixture was heated at reflux. A solution of benzyl 2-(2-(chloromethyl) 
allyl)-3-hydroxypyrrolidine-1-carboxylate (1.0 equiv) in MeCN (0.3 M) was added dropwise to 
the reaction mixture and the reaction was left to stir for 16 h. After completion, aq. NH4Cl was 
added and the product extracted with ethyl acetate. The organic layers were dried over 
anhydrous MgSO4 and the solvent was removed under reduced pressure to afford the crude 
product. The crude residue was purified via flush column chromatography eluting CH2Cl2 : 
MeOH (8 : 2) to afford the corresponding products. 
Benzyl 3-hydroxy-2-(2-((4-oxoquinazolin-3(4H)-yl) methyl) allyl)-3-hydroxypiperidine-1-
carboxylate (140).11 
 
Quinazolin-4(3H)-one (50 mg, 0.03 mmol), K2CO3 (70 mg, 0.05 mmol) and 133 (110 mg, 0.03 
mmol)  were subjected to the general conditions for 16 h to afford the product as a yellow oil 
(113 mg, 77%). δH (400 MHz, CDCl3) 8.30 - 8.26 (m, 1H), 8.10 (s, 1H), 7.80 - 7.70 (m, 2H), 7.55 
- 7.45 (m, 1H), 7.40 - 7.25 (m, 5H), 5.20 - 5.05 (m, 2H), 5.00 - 4.90 (m, 1H), 4.70 - 4.60 (m, 1H), 
4.50 - 4.45 (m, 1H), 4.10 - 4.05 (m, 2H), 3.95 - 3.85 (m, 1H), 2.96 - 2.85 (m, 2H), 2.60 - 2.40 (m, 
2H), 2.00 - 1.90 (m, 2H), 1.85 - 1.65 (m, 1H), 1.50 - 1.35 (m, 2H); δC (101 MHz, CDCl3) 160.3, 
158.4, 148.0, 147.2, 144.1, 136.6, 134.6, 128.4, 127.9, 127.6, 127.2, 126.8, 126.4, 121.9, 
114.1, 67.2, 60.4, 55.4, 49.2, 42.2, 38.8, 34.1, 21.0. 





Quinazolin-4(3H)-one (50 mg, 0.03 mmol), K2CO3 (70 mg, 0.05 mmol) and 134 (110 mg, 0.03 
mmol) were subjected to the general conditions for 16 h to afford the product as a yellow oil 
(118 mg, 80%). Vmax (solid /cm-1) 3389, 2920, 1736, 1666, 1476, 1071; δH (400 MHz, CDCl3) 
8.35 - 8.25 (m, 1H), 8.10 (s, 1H), 7.80 - 7.70 (m, 2H), 7.55 - 7.45 (m, 1H), 7.40 - 7.30 (m, 5H), 
5.20 - 5.05 (m, 2H), 4.95 - 4.90 (m, 1H), 4.85 - 4.70 (m, 1H), 4.45 - 4.30 (m, 1H), 4.10 - 3.90 (m, 
2H), 2.90 - 2.75 (m, 1H), 2.50 - 2.38 (m, 2H), 2.34 - 2.15 (m, 2H), 1.84 - 1.78 (m, 2H), 1.76 - 1.68 
(m, 1H), 1.58 - 1.44 (m, 2H); δC (101 MHz, CDCl3) 160.3, 158.4, 148.0, 147.2, 143.8, 136.4, 
134.7, 128.4, 127.7, 127.6, 127.2, 126.8, 126.4, 121.9, 114.1, 67.2, 60.4, 53.6, 49.3, 42.2, 37.7, 
34.0, 21.0; m/z (ESI) 434 (100%, [M]+); HRMS, found 434.2075 ([C25H27N3O4] requires 
434.2074). 
Benzyl 2-(2-((7-bromo-6-chloro-4-oxoquinazolin-3(4H)-yl) methyl) allyl)-3-
hydroxypiperidine-1-carboxylate (153). 
 
7-Bromo-6-chloroquinazolin-4(3H)-one (83) (50 mg, 0.2 mmol), K2CO3 (40 mg, 0.3 mmol) and 
133 (62 mg, 0.9 mmol) were subjected to the general conditions for 16 h to afford the product 
as a yellow oil (98 mg, 91%). Vmax (solid /cm-1) 3454, 2917, 1738, 1659, 1609, 1465, 1419,1231, 
922; δH (400 MHz, CDCl3) 8.30 (s, 1H), 8.10 (s, 1H), 8.00 (s, 1H),  7.36 - 7.27 (m, 5H), 5.15 - 5.05 
(m, 2H), 4.90 - 4.85 (m, 2H), 4.60 - 4.55 (m, 1H), 3.90 - 3.88 (m, 2H), 3.18 - 3.08 (m, 1H), 2.98 
- 2.88 (m, 2H), 2.56 - 2.48 (m, 1H), 2.32 - 2.28 (m, 2H), 2.00 - 1.90 (m, 2H), 1.85 - 1.70 (m, 2H); 
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δC (101 MHz, CDCl3) 162.5, 158.4, 155.1, 152.6, 146.7, 136.9, 129.7, 128.7, 128.3, 128.2, 128.1, 
127.5, 126.0, 124.9, 111.2, 70.3, 67.4, 56.5, 49.4, 42.2, 35.4, 31.2, 23.2; m/z (ESI) 548 (100%, 
[M(35Cl79Br)]+); HRMS, found 548.0766  ([C25H2579Br35ClN3O4] requires 548.0770). 
Benzyl 2-(2-((6,7-dichloro-4-oxoquinazolin-3(4H)-yl) methyl) allyl)-3-hydroxypiperidine-1-
carboxylate (160).  
 
6, 7-Dichloroquinazolin-4(3H)-one (156) (20 mg, 0.1 mmol), K2CO3 (19 mg, 0.2 mmol) and 133 
(30 mg, 0.1 mmol) were subjected to the general conditions for 16 h to afford the product as 
a yellow oil (30 mg, 80%). Vmax (solid /cm-1) 3440, 2918, 2849, 1738, 1667, 1601, 1076, 695; δH 
(400 MHz, CDCl3) 8.35 (s, 1H), 8.10 (s, 1H), 7.85 (s, 1H), 7.40 - 7.28 (m, 5H), 5.20 - 5.10 (m, 2H), 
4.95 - 4.90 (m, 2H), 4.60 - 4.50 (m, 1H), 4.10 - 4.08 (m, 2H), 3.90 - 3.84 (m, 1H), 3.00 - 2.85 (m, 
2H), 2.50 - 2.40 (m, 1H), 2.20 - 2.15 (m, 2H), 1.80 - 1.70 (m, 2H), 1.50 - 1.45 (m, 2H); δC (101 
MHz, CDCl3) 162.0, 159.4, 155.6, 152.2, 148.3, 136.5, 129.7, 129.1, 128.5, 128.1, 127.6, 127.3, 
126.0, 121.4, 114.3, 70.3, 67.3, 55.4, 49.5, 38.8, 34.2, 31.9, 22.7;  m/z (ESI) 502 (100%, 
[M(35Cl2)]+); HRMS, found 502.1299 ([C25H2535Cl2N3O4] requires 502.1295). 





7-Bromo-6-fluoroquinazolin-4(3H)-one (157) (100 mg, 0.4 mmol), K2CO3 (85 mg, 0.6 mmol) 
and 133 (132 mg, 0.4 mmol) were subjected to the general conditions for 16 h to afford the 
product as a yellow oil (186 mg, 85%). Vmax (solid /cm-1) 3454, 2917, 1738, 1659, 1465, 1234, 
696; δH (400 MHz, CDCl3) 8.10 - 7.99 (m, 3H), 7.35 - 7.27 (m, 5H), 5.20 - 5.15 (m, 2H), 4.99 - 
4.93 (m, 2H), 4.70 - 4.50 (m, 1H), 4.20 - 4.00 (m, 2H), 3.90 - 3.80 (m, 1H), 3.02 - 2.80 (m, 2H), 
2.56 - 2.40 (m, 1H), 2.23 - 2.13 (m, 2H), 2.00 - 1.90 (m, 2H), 1.85 - 1.70 (m, 2H); δC (101 MHz, 
CDCl3) 160.0, 158.7 (d, J = 250.0 Hz), 147.5, 145.1, 139.8, 136.5, 128.9, 128.5, 128.3 128.0, 
127.6, 122.3, 117.3, 114.3 (d, J = 27.0 Hz), 112.7 (d, J = 25.0 Hz), 70.3, 67.3, 55.4, 49.5, 40.1, 
38.8, 34.1, 22.7; δF (376 MHz, CDCl3) - 106.7; m/z (ESI) 532 (100%, [M(79Br)]+); HRMS, found 
532.1074 ([C25H2579BrFN3O4] requires 532.1068). 
Benzyl 2-(2-((6, 7-bis(2-methyoxyethoxy)-4-oxoquinazolin-3(4H)-yl) methyl) allyl)-3-
hydroxypiperidine-1-carboxylate (162). 
 
6, 7-Bis(2-methoxyethoxy) quinazolin-4(3H)-one (158) (20 mg, 0.06 mmol), K2CO3 (14 mg, 0.10 
mmol) 133 (22 mg, 0.06 mmol)  were subjected to the general conditions for 16 h to afford 
the product as a clear oil (28 mg, 69%). Vmax (solid /cm-1) 3386, 2928, 1666, 1607, 1496, 1271, 
727; δH (400 MHz, CDCl3) 8.05 (s, 1H), 7.65 (s, 1H), 7.40 - 7.30 (m, 5H), 7.15 (s, 1H), 5.18 - 5.12 
(m, 2H), 4.97 - 4.91 (m, 1H), 4.66 - 4.63 (m, 1H), 4.30 - 4.25 (m, 4H), 3.90 - 3.80 (m, 4H), 3.48 
(s, 6H), 2.98 - 2.81 (m, 2H), 2.55 - 2.45 (m, 1H), 2.42 - 2.30 (m, 2H), 2.25 - 2.15 (m, 2H), 2.00 - 
1.90 (m, 2H), 1.85 - 1.70 (m, 2H), 1.50 - 1.40 (m, 2H); δC (101 MHz, CDCl3) 160.3, 158.5, 154.8, 
152.6, 148.8, 145.8, 142.3, 136.6, 128.4, 128.0, 127.7, 116.0, 109.2, 107.3, 106.9, 70.6, 70.5, 
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68.6, 68.5, 67.2, 59.4, 59.3, 55.5, 49.4, 49.2, 38.8, 34.1, 29.7, 22.6; m/z (ESI) 582 (100%, [M]+); 
HRMS, found 582.2823 ([C31H39N3O8] requires 582.2810). 
Benzyl 2-(2-((6-bromo-4-oxoquinazolin-3(4H)-yl) methyl) allyl)-3-hydroxypiperidine-1-
carboxylate (163). 
 
6-Bromoquinazolin-4(3H)-one (159) (139 mg, 0.4 mmol), K2CO3 (128 mg, 0.9 mmol) and 133 
(200 mg, 0.4 mmol) were subjected to the general conditions for 16 h to afford the product 
as a yellow oil (316 mg, 72%). Vmax (solid /cm-1) 3434, 2934, 2860, 1669, 1608, 1256, 729; δH 
(400 MHz, CDCl3) 8.40 (s, 1H), 8.10 (s, 1H), 7.80 (d, 1H, J = 9.0 Hz), 7.55 (d, 1H, J = 9.0 Hz), 7.40 
- 7.20 (m, 5H), 5.20 - 5.15 (m, 2H), 4.99 - 4.93 (m, 2H), 4.70 - 4.50 (m, 1H), 4.20 - 4.00 (m, 2H), 
3.90 - 3.80 (m, 1H), 3.02 - 2.80 (m, 2H), 2.56 - 2.40 (m, 1H), 2.23 - 2.13 (m, 2H), 2.00 - 1.90 (m, 
2H), 1.85 - 1.70 (m, 2H); δC (101 MHz, CDCl3) 161.1, 159.7, 147.5, 146.9, 145.6, 140.0, 137.4, 
129.3, 129.2, 128.4, 127.9, 127.5, 123.3, 120.8, 114.1, 67.2, 67.0, 55.4, 49.2, 38.8, 34.1, 29.6, 
21.0; m/z (ESI) 513 (100%, [M(79Br)]+); HRMS, found 513.1215 ([C25H2679BrN3O4] requires 
513.1211). 




OsO4 (a few crystals) was added to a suspension of benzyl 3-hydroxy-2-(2-((4-oxoquinazolin-
3(4H)-yl) methyl) allyl)-3-hydroxypiperidine-1-carboxylate (1.0 equiv) and NaIO4 (2.0 equiv) in 
THF (0.1 M) and water (0.2 M), and the solution was left to stir for 16 h. After completion, a 
saturated solution of Na2S2O5 was added and the organic layers were extracted with ethyl 
acetate. The combined organic layers were dried over anhydrous MgSO4 and the solvent was 
removed under reduced pressure to afford the crude product. The crude residue was purified 
via flash column chromatography eluting CH2Cl2 : MeOH (8 : 2) to afford the corresponding 
ketone.  
To the ketone substrate (1.0 equiv) in a round bottom flask was added methanol (0.2 M) and 
HBr (33 wt% in AcOH) (100.0 equiv) at 0 °C. The mixture was stirred for 30 mins and after 
completion the solvent was removed in vacuo, purification by recrystallization from ethanol 
afford the corresponding products. 
3-Hydroxypiperidin-2-yl-2-oxopropyl quinazolin-4(3H)-one hydrobromide (146). 
 
140 (113 mg, 0.2 mmol) was subjected to the general conditions to afford the title product as 
a colourless solid (88 mg, 89%) Mp > 250 °C. Vmax (solid /cm-1) 3329, 2924, 1704, 1660, 1507, 
1028 ; δH (400 MHz, MeOD-d4) 8.90 (s, 1H), 8.40 - 8.30 (m, 1H), 8.10 - 7.95 (m, 1H), 7.85 - 7.70 
(m, 2H), 5.30 (d, 1H, J = 17.5 Hz), 5.22 (d, 1H, J = 17.5 Hz), 3.75 - 3.65 (m, 1H), 3.55 - 3.50 (m, 
2H), 3.45 (d, 1H, J = 4.5 Hz), 3.05 (dd, 1H, J = 15.0, 4.0 Hz), 3.01 (dd, 1H, J = 15.0, 4.0 Hz), 2.16 
- 2.04 (m, 2H), 1.88 - 1.76 (m, 1H), 1.68 - 1.60 (m, 1H); δC (101 MHz, MeOD-d4) 201.1, 158.0, 
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151.0, 147.4, 138.4, 136.8, 129.5, 127.5, 120.7, 66.9, 56.6, 55.2, 43.5, 39.0, 30.1, 19.9; m/z 




153 (88 mg, 0.2 mmol) was subjected to the general conditions to afford the title product as 
a colorless solid (55 mg, 70%) Mp > 250 °C. Vmax (solid /cm-1) 3290, 2943, 1705, 1677, 1598, 
1080; δH (400 MHz, MeOD-d4) 8.32 (s, 1H), 8.22 (s, 1H), 8.12 (s, 1H), 5.11 (d, 1H, J = 17.5 Hz), 
5.02 (d, 1H, J = 17.5 Hz), 3.70 - 3.60 (m, 1H), 3.55 - 3.45 (m, 2H), 3.40 (d, 1H, J = 5.0 Hz), 3.05 
(dd, 1H, J = 15.0, 4.0 Hz), 3.00 (dd, 1H, J = 15.0, 4.0 Hz), 2.15 - 2.00 (m, 2H), 1.85 - 1.75 (m, 
1H), 1.65 - 1.55 (m, 1H); δC (101 MHz, MeOD-d4) 201.4, 158.0, 151.0, 147.5, 138.4, 136.8, 
129.5, 127.5, 120.7, 66.8, 56.8, 54.4, 43.6, 38.4, 30.0, 20.0; m/z (ESI) 416 (100%, 
[M(35Cl79Br)]+); HRMS, found 416.0193 ([C16H1779Br35ClN3O3] requires 416.0193). 
6,7-Dichloro-3-(3-hydroxypiperidin-2-yl)-2-oxopropyl) quinazolin-4(3H)-one hydrobromide 
(165). 
 
160 (30 mg, 0.05 mmol) was subjected to the general conditions to afford the title product as 
a colourless solid (24 mg, 94%) Mp > 250 °C. Vmax (solid /cm-1) 3332, 2925, 1705, 1658, 1508 , 
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1031; δH (400 MHz, MeOD-d4) 8.34 (s, 1H), 8.22 (s, 1H), 7.94 (s, 1H), 5.11 (d, 1H, J = 18.0 Hz), 
5.02 (d, 1H, J = 18.0 Hz), 3.70 - 3.60 (m, 1H), 3.52 - 3.45 (m, 2H), 3.41 (d, 1H, J = 5.0 Hz), 3.08 
(dd, 1H, J = 15.0, 4.0 Hz), 3.00 (dd, 1H, J = 15.0, 4.0 Hz), 2.15 - 2.00 (m, 2H), 1.85 - 1.75 (m, 
1H), 1.67 - 1.57 (m, 1H); δC (101 MHz, MeOD-d4) 201.1, 157.9, 151.0, 147.5, 138.4, 136.8, 
129.5, 127.5, 120.7, 66.5, 56.7, 54.3, 43.5, 38.3, 29.9, 19.8; m/z (ESI) 308 (100%, [M(35Cl2)]+); 




161 (69 mg, 0.1 mmol) was subjected to the general conditions to afford the title product as 
a grey solid (31 mg, 51%) Mp 246 - 247 °C. Vmax (solid /cm-1) 3332, 2925, 1705, 1658, 1508, 
1031; δH (400 MHz, DMSO-d6) 8.25 (s, 1H), 8.19 (d, 1H, J = 10.0 Hz), 7.97 (d, 1H, J = 10.0 Hz), 
5.13 (d, 1H, J = 18.0 Hz), 5.07 (d, 1H, J = 18.0 Hz), 3.55 - 3.45 (m, 1H), 3.25 - 3.20  (m, 2H), 3.15 
(d, 1H, J = 5.0 Hz), 2.91 (dd, 1H, J = 15.5, 4.0 Hz), 2.87 (dd, 1H, J = 15.5, 4.0 Hz), 2.90 - 1.90 (m, 
2H), 1.85 - 1.80 (m, 1H), 1.65 - 1.55 (m, 1H); δC (101 MHz, DMSO-d6) 201.5, 159.5, 157.0 (d, J 
= 260.0 Hz), 149.2, 145.9, 133.0, 128.0, 117.0 (d, J = 24.0 Hz), 112.5 (d, J = 24.0 Hz), 67.5, 57.0, 
55.0, 43.5, 43.3, 31.0, 20.5; δF (376 MHz, DMSO-d6) - 108.9; m/z (ESI) 401 (100%, [M(79Br)]+); 
HRMS, found 401.0090 ([C16H1779BrFN3O3] requires 401.1010). 
3-Hydroxypiperidin-2-yl-2-oxopropyl quinazolin-6,7-bis(2-methoxyethoxy)quinazolin-




162 (28 mg, 0.04 mmol) was subjected to the general conditions to afford the title product as 
a colourless solid (20 mg, 80%) Mp > 250 °C. Vmax (solid /cm-1) 3346, 2926, 1659, 1604, 1382, 
987; δH (400 MHz, MeOD-d4) 9.20 (s, 1H), 7.70 (s, 1H), 7.27 (s, 1H), 5.33 (d, 1H, J = 18.0 Hz), 
5.26 (d, 1H, J = 18.0 Hz), 4.40 - 4.30 (m, 4H), 3.90 - 3.80 (m, 4H), 3.70 - 3.60 (m, 1H), 3.52 - 
3.45 (m, 2H), 3.43 (s, 6H), 3.41 (d, 1H, J = 5.0 Hz), 3.08 (dd, 1H, J = 15.0, 4.0 Hz), 3.00 (dd, 1H, 
J = 15.0, 4.0 Hz), 2.15 - 2.00 (m, 2H), 1.85 - 1.75 (m, 1H), 1.67 - 1.57 (m, 1H); δC (101 MHz, 
MeOD-d4) 201.0, 157.5, 156.3, 150.6, 149.1, 134.9, 113.5, 107.5, 102.5, 70.5, 70.3, 69.5, 69.0, 
67.0, 58.1, 58.0, 56.6, 55.2, 43.4, 39.0, 30.0, 20.0; m/z (ESI) 450 (100%, [M]+); HRMS, found 
450.2237 ([C22H31N3O7] requires 450.2235). 
6-bromo-3-(3-(3-hydroxypiperidin-2-yl)-2-oxopropyl) quinazolin-4(3H)-one hydrobromide 
(167). 
 
163 (25 mg, 0.04 mmol) was subjected to the general conditions to afford the title product as 
a colourless solid (12 mg, 54%) Mp 221 - 222 °C. Vmax (solid /cm-1) 3088, 2671, 1766, 1713, 
1631, 784; δH (400 MHz, DMSO-d6) 8.30 (s, 1H), 8.25 (s, 1H), 8.05 (d, 1H, J = 9.0 Hz), 7.70 (d, 
1H, J = 9.0 Hz), 5.14 (d, 1H, J = 18.0 Hz), 5.08 (d, 1H, J = 18.0 Hz), 3.55 - 3.50 (m, 1H), 3.40 - 
3.30 (m, 2H), 3.25 - 3.15 (m, 1H), 2.95 - 2.85 (m, 1H), 2.00 - 1.90 (m, 1H), 1.85 - 1.80 (m, 2H), 
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1.70 - 1.60 (m, 1H), 1.55 - 1.40 (m, 1H); δC (101 MHz, DMSO-d6) 201.5, 159.3, 149.2, 147.4, 
138.0, 130.2, 128.5, 123.3, 120.2, 67.2, 56.6, 54.8, 43.5, 43.4, 30.9, 20.6; m/z (ESI) 380 (100%, 
[M (79Br)]+); HRMS, found 380.0613 ([C16H1879BrN3O3] requires 380.0604). 
General Procedure for the Synthesis of Febrifugine Analogue 145. 
 
 OsO4 (a few crystals) was added to a suspension of benzyl 3-hydroxy-2-(2-((4-oxoquinazolin-
3(4H)-yl) methyl) allyl)-3-hydroxypiperidine-1-carboxylate (1.0 equiv) and NaIO4 (2.0 equiv) in 
THF (0.1 M) and water (0.2 M), and the solution was left to stir for 16 h. After completion, a 
saturated solution of Na2S2O5 was added and the organic layers were extracted with ethyl 
acetate. The combined organic layers were dried over anhydrous MgSO4 and the solvent was 
removed under reduced pressure to afford the crude product. The crude residue was purified 
via flush column chromatography eluting CH2Cl2 : MeOH (8 : 2) to afford the corresponding 
ketone.  
To the ketone substrate (1.0 equiv) in a round bottom flask was added dichloromethane (0.2 
M) and HBr (33 wt% in AcOH) (100.0 equiv) at 0 °C. The mixture was stirred for 30 mins and 
after completion, aq. NaOH was added and the organic layer extracted with ethyl acetate (2 
x 20 mL). The combined organic layers were dried over anhydrous MgSO4 and the solvent 
removed under reduced pressure to afford the crude product, which was purified by flash 
column chromatography eluting CH2Cl2 : MeOH (8 : 2) to afford the corresponding products. 
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Hydroxyoctahydrofuro [3,2-b] pyridine-2-yl methyl quinazolin-4(3H)-one (145).11 
 
141 (118 mg, 0.3 mmol) was subjected to the general conditions to afford the title product as 
a yellow oil (27 mg, 34%). δH (400 MHz, CDCl3) 8.35 - 8.25 (m, 1H), 8.10 (s, 1H), 7.80 - 7.70 (m, 
2H), 7.55 - 7.45 (m, 1H), 4.39 (d, 1H, J = 13.9 Hz), 4.19 (d, 1H, J = 13.9 Hz), 3.94 - 3.91 (m, 1H), 
3.34 - 3.32 (m, 1H), 3.04 - 3.05 (m, 2H), 2.56 - 2.53 (m, 1H), 2.20 - 2.05 (m, 1H), 1.90 - 1.80 (m, 
2H), 1.65 - 1.55 (m, 2H), 1.50 - 1.45 (m, 2H); δC (101 MHz, CDCl3) 160.5, 149.2, 149.1, 134.3, 
132.6, 129.3, 126.9, 121.9, 105.4, 77.6, 55.7, 52.4, 49.9, 44.5, 26.7, 20.0. 
 
148 obtained as a yellow oil (58 mg, 50%). Vmax (solid /cm-1) 3072, 2974, 1722, 1676, 1646, 
1354, 786; δH (400 MHz, CDCl3) 8.35 - 8.25 (m, 1H), 7.95 (s, 1H), 7.85 - 7.70 (m, 2H), 7.55 - 7.45 
(m, 1H), 5.00 (s, 2H), 3.82 - 3.76 (m, 2H), 2.98 -2.94 (m, 2H), 2.71 - 2.66 (m, 2H), 2.51 - 2.46 
(m, 2H), 1.94 - 1.85 (m, 2H); δC (101 MHz, CDCl3) 202.5, 176.6, 161.0, 148.8, 148.2, 135.0, 
134.4, 127.8, 127.6, 121.9, 60.5, 54.5, 37.9, 35.7, 27.5, 22.6; m/z (ESI) 284 (100%, [M]+); HRMS, 
found 284.1395 ([C16H17N3O2] requires 284.1394). 





NaBH4 (2.0 eq) was added to a suspension of benzyl 3-hydroxy-2-(2-((4-oxoquinazolin-3(4H)-
yl) methyl) allyl)-3-hydroxypiperidine-1-carboxylate 142 (1.0 equiv) in MeOH (0.1 M), and the 
solution was left to stir for 2 h. After completion, a saturated solution of NaHCO3 was added 
and the organic layers were extracted with ethyl acetate. The combined organic layers were 
dried over anhydrous MgSO4 and the solvent was removed under reduced pressure to afford 
the crude product. The crude residue was purified via isocratic preparative high performance 
liquid chromatography (HPLC) eluting MeCN : H2O (3 : 7) to afford the corresponding 
protected febrifuginol analogues. 
To each of the alcohol substrates (1.0 equiv) in a round bottom flask was added methanol (0.2 
M) and HBr (33 wt% in AcOH) (100.0 equiv) at 0 °C. The mixture was stirred for 30 mins and 
after completion the solvent was removed in vacuo, purification by recrystallization from 
ethanol afford the corresponding products. 
Febrifuginol hydrobromide 172. 
 
172 colourless solid (8 mg, 45%) Mp 198 - 199 °C. Vmax (solid /cm-1) 3294, 30.70, 2974, 1672, 
1473; δH (400 MHz, MeOD-d4) 9.60 (s, 1H), 8.45 (d, 1H, J = 8.0 Hz), 8.15 - 8.05 (m, 1H), 7.90 - 
7.80 (m, 2H), 4.55 (dd, 1H, J = 10.0, 4.0 Hz), 4.40 - 4.32 (m, 1H), 4.10 - 4.02 (m, 1H), 3.40 - 3.30 
(m, 2H), 3.25 - 3.20 (m, 1H), 3.10 - 2.95 (m, 1H), 2.50 - 2.40 (m, 2H), 2.20 - 2.00 (m, 2H), 1.85 
- 1.75 (m, 1H), 1.65 - 1.55 (m, 2H); δC (101 MHz, MeOD-d4) 161.2, 153.7, 151.3, 134.3, 127.9, 
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125.6, 124.2, 121.0, 73.7, 66.9, 58.4, 51.4, 45.4, 39.7, 32.0, 24.1; m/z (ESI) 304 (100%, [M]+); 
HRMS, found 304.1657 ([C16H21N3O3] requires 304.1656). 
Epi-febrifuginol hydrobromide (173). 
 
173 colourless solid (28 mg, 80%) Mp 200 - 201 °C . Vmax (solid /cm-1) 3294, 30.70, 2974, 1672, 
1473; δH (400 MHz, MeOD-d4) 9.50 (s, 1H), 8.40 (d, 1H, J = 8.0 Hz), 8.10 - 8.05 (m, 1H), 7.85 - 
7.80 (m, 2H), 4.51 (dd, 1H, J = 10.0, 4.0 Hz), 4.40 - 4.35 (m, 1H), 4.12 - 4.04 (m, 1H), 3.72 - 3.64 
(m, 2H), 3.08 - 3.00 (m, 1H), 2.20 - 2.00 (m, 4H), 1.85 - 1.75 (m, 2H), 1.65 - 1.55 (m, 2H); δC 
(101 MHz, MeOD-d4) 161.2, 153.7, 151.3, 134.3, 127.9, 125.6, 124.2, 121.0, 73.7, 66.9, 58.4, 
51.4, 45.4, 39.7, 32.0, 24.1; m/z (ESI) 304 (100%, [M]+); HRMS, found 304.1656 ([C16H21N3O3] 
requires 304.1656).  
 Synthesis of benzyl 6-oxa-2-azabicyclo [3.1.0]hexane-2-carboxylate (181). 
 
Oxone monopersulfate (12.0 g, 39.3 mmol) was added portion wise to a solution of sodium 
bicarbonate (16.5 g, 19.6 mmol) in water (100 mL), and the mixture was allowed to stir for 10 
mins. To this solution was added acetone (60 mL) and benzyl 2,3-dihydro-1H-pyrrole-1-
carboxylate (1.0 g, 4.9 mmol). The mixture was allowed to stir for 16 h at room temperature. 
After completion, water (100 mL) was added and the organic layer extracted with ethyl 
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acetate (2 x 50 mL). The combined organic layers were dried over anhydrous MgSO4 and the 
solvent removed under reduced pressure to afford the crude product, which was purified by 
flash column chromatography eluting with cyclohexane : EtOAc (2 : 8) to afford the title 
product as a clear oil (0.7 g, 65%). Vmax (solid /cm-1) 3375, 2947, 1673, 1255, 987;  δH (400 
MHz, CDCl3) 7.40 - 7.35 (m, 5H), 5.16 (s, 2H), 4.39 (d, 1H, J = 4.0 Hz), 3.63 - 3.57 (m, 1H), 3.09 
- 3.02 (m, 2H), 2.29 - 2.19 (m, 2H); δC (101 MHz, CDCl3) 156.0, 136.2, 128.6, 128.5, 128.2, 
128.1, 127.9, 86.6, 67.3, 44.3, 42.8, 29.9; m/z (ESI) 219 (100%, [M]+); HRMS, found 219.0895  
([C12H13NO3] requires 219.0890). 
Synthesis of benzyl 2-(2-(chloromethyl)allyl)-3-hydroxypyrrolidine-1-carboxylate (183). 
 
To a solution of benzyl 6-oxa-2-azabicyclo [3.1.0]hexane-2-carboxylate (476 mg, 1.7 mmol) 
and chlorotrimethylsilane (1.1 g, 6.8 mmol) in dichloromethane (10 mL) at -78 °C, BF3.OEt2 
(242 mg, 1.7 mmol) was added. The reaction was allowed to stir overnight. NaHCO3 (aq) (20 
mL) was added and the reaction mixture was extracted with EtOAc (2 x 20 mL). The combined 
organic layers were dried over MgSO4 and the solvent was removed under reduced pressure 
to afford the product as a mixture of diastereoisomers which were purified via isocratic 
preparative high performance liquid chromatography (HPLC) eluting MeCN  : H2O (4 : 6) to 
afford the corresponding products. 183 as a clear oil (87 mg, 16%); Vmax (solid /cm-1) 3444, 
2938, 2516, 2159, 2028, 1670, 1424; δH (400 MHz, CDCl3) 7.42 - 7.36 (m, 5H), 5.15 - 5.13 (m, 
4H), 4.51 - 4.45 (m, 1H), 4.32 - 4.24 (m, 1H), 4.16 - 4.04 (m, 2H), 3.64 - 3.50 (m, 2H), 3.55 - 3.49 
(m, 2H), 2.63 - 2.55 (m, 2H); δC (101 MHz, CDCl3) 156.0, 148.1, 137.0, 128.3, 128.2, 128.1, 
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127.9, 120.7, 76.3, 67.0, 59.1, 49.7, 44.0, 37.0, 33.1; m/z (ESI) 310 (100%, [M(35Cl)]+); HRMS, 
found 310.1205  ([C16H20NO335Cl] requires 310.1204). 
184 clear oil (42 mg, 9%). Vmax (solid /cm-1) 3444, 2938, 2516, 2159, 2028, 1670, 1424; δH  (400 
MHz, CDCl3) 7.39 - 7.32 (m, 5H), 5.24 - 5.06 (m, 4H), 4.23 - 4.19 (m, 1H), 4.06 - 4.02 (m, 1H), 
3.97 - 3.90 (m, 2H), 3.72 - 3.64 (m, 2H), 3.56 - 3.52 (m, 2H), 2.60 - 2.50 (m, 2H); δC (101 MHz, 
CDCl3) 155.9, 148.1, 137.1, 128.3, 128.2, 128.1, 127.9, 120.7, 76.2, 67.1, 59.0, 49.7, 44.1, 37.3, 
33.3; m/z (ESI) 310 (100%, [M(35Cl)]+); HRMS, found 310.1203  ([C16H20NO335Cl] requires 
310.1204). 
General Procedure for the Synthesis of substrates 185 and 186. 
 
Potassium carbonate (1.5 equiv) was added to a suspension of quinazolinone (1.0 equiv) in 
MeCN (0.1 M) and the mixture was heated at reflux. A solution of benzyl 2-(2-
(chloromethyl)allyl)-3-hydroxypyrrolidine-1-carboxylate (1.0 equiv) in MeCN (0.3 M) was 
added dropwise to the reaction mixture and the reaction was left to stir for 16 h. After 
completion, aq. NH4Cl was added and the product extracted with ethyl acetate. The organic 
layers were dried over anhydrous MgSO4 and the solvent was removed under reduced 
pressure to afford the crude product. The crude residue was purified via flash column 






183 (42 mg, 0.1 mmol) was subjected to the general conditions to afford the title product as 
a yellow oil (39 mg, 70%). Vmax (solid /cm-1) 3454, 3023, 2917, 1738, 1706, 1659, 1609, 1231; 
δH (400 MHz, CDCl3) 8.30 - 8.26 (m, 1H), 8.10 (s, 1H), 7.80 - 7.70 (m, 2H), 7.55 - 7.45 (m, 1H), 
7.40 - 7.25 (m, 5H), 5.20 - 5.05 (m, 2H), 5.00 - 4.90 (m, 1H), 4.70 - 4.60 (m, 1H), 4.50 - 4.45 (m, 
1H), 4.10 - 4.05 (m, 2H), 3.95 - 3.85 (m, 1H), 2.60 - 2.40 (m, 2H), 2.00 - 1.90 (m, 2H), 1.50 - 1.35 
(m, 2H); δC (101 MHz, CDCl3) 160.3, 158.4, 148.0, 147.2, 144.1, 136.6, 134.6, 128.4, 127.9, 
127.6, 127.2, 126.8, 126.4, 121.9, 114.1, 67.2, 60.4, 55.4, 49.2, 42.2, 38.8, 34.1; m/z (ESI) 420 




184 (87 mg, 0.3 mmol) was subjected to the general conditions to afford the title product as 
a yellow oil (77 mg, 66%). Vmax (solid /cm-1) 3440, 3129, 2918, 1738, 1660, 1601, 1423; δH (400 
MHz, CDCl3) 8.29 - 8.25 (m, 1H), 8.10 (s, 1H), 7.79 - 7.70 (m, 2H), 7.53 - 7.40 (m, 1H), 7.36 - 
7.25 (m, 5H), 5.18 - 5.05 (m, 2H), 5.00 - 4.89 (m, 1H), 4.65 - 4.60 (m, 1H), 4.50 - 4.45 (m, 1H), 
4.10 - 4.04 (m, 2H), 3.95 - 3.85 (m, 1H), 2.63 - 2.44 (m, 2H), 2.04 - 1.94 (m, 2H), 1.50 - 1.35 (m, 
2H); δC (101 MHz, CDCl3) 160.3, 158.4, 148.0, 147.2, 144.1, 136.6, 134.6, 128.3, 127.9, 127.7, 
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127.3, 126.8, 126.4, 121.9, 114.3, 67.1, 60.4, 55.0, 49.2, 42.2, 38.8, 33.9; m/z (ESI) 420 (100%, 
[M]+); HRMS, found 420.1919 ([C24H25N3O4] requires 420.1918). 
General Procedure for the Synthesis of substrates 187 and 188. 
 
OsO4 (a few crystals) was added to a suspension of benzyl 3-hydroxy-2-(2-((4-oxoquinazolin-
3(4H)-yl) methyl) allyl)pyrrolidine-1-carboxylate (1.0 equiv) and NaIO4 (2.0 equiv) in THF (0.1 
M) and water (0.2 M), and the solution was left to stir for 16 h. After completion, a saturated 
solution of Na2S2O5 was added and the organic layers were extracted with ethyl acetate. The 
combined organic layers were dried over anhydrous MgSO4 and the solvent was removed 
under reduced pressure to afford the crude product. The crude residue was purified via flush 




185 (36 mg, 0.08 mmol) was subjected to the general conditions to afford the title product as 
a yellow oil (22 mg, 60%). Vmax (solid /cm-1) 3365, 3033, 2932, 1732, 1688, 1610, 1041; δH (400 
MHz, CDCl3) 8.30 - 8.26 (m, 1H), 8.10 (s, 1H), 7.80 - 7.70 (m, 2H), 7.55 - 7.45 (m, 1H), 7.40 - 
7.25 (m, 5H), 5.20 - 5.05 (m, 2H), 5.00 - 4.90 (d, 1H, J = 17.5 Hz), 4.70 - 4.60 (d, 1H, J = 17.5 
Hz), 4.50 - 4.45 (m, 1H), 4.10 - 4.05 (m, 2H), 3.95 - 3.85 (m, 1H), 2.60 - 2.40 (m, 2H), 1.50 - 1.35 
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(m, 2H); δC (101 MHz, CDCl3) 201.0, 160.9, 155.2, 147.7, 146.8, 136.6, 134.7, 128.7, 128.5, 
128.3, 128.1, 127.8, 127.6, 126.8, 121.6, 67.0, 63.0, 54.4, 54.2, 44.6, 43.9, 31.5; m/z (ESI) 422 




186 (77 mg, 0.1 mmol) was subjected to the general conditions to afford the title product as 
a yellow oil (46 mg, 60%). Vmax (solid /cm-1) 3297, 2925, 1734, 1661, 1607, 1263; δH (400 MHz, 
CDCl3) 8.29 - 8.25 (m, 1H), 8.10 (s, 1H), 7.81 - 7.72 (m, 2H), 7.55 - 7.45 (m, 1H), 7.37 - 7.25 (m, 
5H), 5.20 - 5.05 (m, 2H), 5.10 - 5.05 (m, 1H), 4.89 - 4.80 (m, 1H), 4.79 - 4.75 (m, 1H), 4.50 - 4.45 
(m, 2H), 3.95 - 3.85 (m, 1H), 2.60 - 2.40 (m, 2H), 1.48 - 1.38 (m, 2H); δC (101 MHz, CDCl3) 201.1, 
161.0, 155.2, 147.9, 146.7, 136.6, 134.6, 128.7, 128.5, 128.3, 128.1, 127.8, 127.5, 126.7, 
121.7, 67.2, 63.0, 54.4, 54.2, 44.6, 43.9, 31.5; m/z (ESI) 422 (100%, [M]+); HRMS, found 







The X-ray crystallography data used to assign the stereochemistry of the compounds listed 




 3-(3- (3-hydroxypiperidin-2-yl)-2-oxopropyl) quinazolin-4 (3H)-one (147). 











Table 1.  Crystal data and structure refinement for 147. 
Identification code  ohj328_a 
Empirical formula  C16 H19 N3 O3 
Formula weight  301.34 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 10.2591(6) Å α = 90°. 
 b = 9.6617(5) Å β = 90°. 
 c = 30.5377(16) Å  = 90°. 
Volume 3026.9(3) Å3 
Z 8 
Density (calculated) 1.323 Mg/m3 
Absorption coefficient 0.762 mm-1 
F(000) 1280 
Crystal size 0.200 x 0.080 x 0.040 mm3 
Theta range for data collection 2.894 to 66.664°. 
Index ranges -11<=h<=12, -11<=k<=11, -29<=l<=36 
Reflections collected 12393 
Independent reflections 2658 [R(int) = 0.1251] 
Completeness to theta = 66.664° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.99 and 0.82 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2658 / 0 / 200 
Goodness-of-fit on F2 1.517 
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Final R indices [I>2sigma(I)] R1 = 0.0784, wR2 = 0.0831 
R indices (all data) R1 = 0.1345, wR2 = 0.0889 
Extinction coefficient n/a 
Largest diff. peak and hole 0.276 and -0.313 e.Å-3 
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 Table 8.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) 
for ohj328_a.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________
_____  
 x y z U(eq) 
___________________________________________________________________________
_____   
O(1) 7899(2) 6118(2) 3942(1) 33(1) 
O(2) 5283(2) 6482(2) 4685(1) 31(1) 
O(3) 6482(2) 10018(2) 5761(1) 26(1) 
N(1) 6127(2) 7492(2) 3869(1) 21(1) 
N(2) 4668(2) 7372(2) 3269(1) 25(1) 
N(3) 6122(2) 6229(2) 5646(1) 19(1) 
C(1) 6954(3) 6467(3) 3720(1) 22(1) 
C(2) 6610(3) 5916(3) 3293(1) 19(1) 
C(3) 7379(3) 4902(3) 3093(1) 33(1) 
C(4) 7043(4) 4383(3) 2693(1) 39(1) 
C(5) 5939(4) 4868(3) 2480(1) 39(1) 
C(6) 5173(3) 5857(3) 2672(1) 31(1) 
C(7) 5494(3) 6399(3) 3083(1) 21(1) 
C(8) 5035(3) 7863(3) 3642(1) 24(1) 
C(9) 6443(3) 8195(3) 4278(1) 27(1) 
C(10) 6078(3) 7407(3) 4684(1) 21(1) 
C(11) 6749(3) 7927(3) 5087(1) 23(1) 
C(12) 6061(3) 7707(3) 5521(1) 20(1) 
C(13) 6687(3) 8588(3) 5875(1) 20(1) 
C(14) 6128(3) 8302(3) 6325(1) 26(1) 
C(15) 6125(3) 6764(3) 6430(1) 26(1) 





 Table 9.   Bond lengths [Å] and angles [°] for  ohj328_a. 
_____________________________________________________  
O(1)-C(1)  1.230(3) 
O(2)-C(10)  1.210(3) 
O(3)-C(13)  1.441(3) 
O(3)-H(3)  0.8400 
N(1)-C(8)  1.366(3) 
N(1)-C(1)  1.381(3) 
N(1)-C(9)  1.457(3) 
N(2)-C(8)  1.288(3) 
N(2)-C(7)  1.388(3) 
N(3)-C(12)  1.479(3) 
N(3)-C(16)  1.482(3) 
N(3)-H(3N)  0.9923 
C(1)-C(2)  1.453(4) 
C(2)-C(7)  1.392(4) 
C(2)-C(3)  1.398(4) 
C(3)-C(4)  1.366(4) 
C(3)-H(3A)  0.9500 
C(4)-C(5)  1.387(4) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.368(4) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.401(4) 
C(6)-H(6)  0.9500 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.503(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.498(4) 
C(11)-C(12)  1.516(3) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(13)  1.518(3) 
C(12)-H(12)  1.0000 
C(13)-C(14)  1.514(3) 
C(13)-H(13)  1.0000 
C(14)-C(15)  1.521(3) 
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C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-C(16)  1.508(3) 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-H(16A)  0.9900 
























































































 Table 10.   Anisotropic displacement parameters  (Å2x 103) for ohj328_a.  The anisotropic 
displacement factor exponent takes the form:  -2 2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
___________________________________________________________________________
___  
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________
___  
O(1) 29(1)  31(1) 38(1)  10(1) -10(1)  0(1) 
O(2) 44(1)  27(1) 23(1)  1(1) -1(1)  -19(1) 
O(3) 26(1)  15(1) 36(1)  -3(1) 5(1)  -1(1) 
N(1) 26(2)  18(1) 18(1)  -1(1) 0(1)  -2(1) 
N(2) 29(2)  23(1) 24(1)  4(1) -1(1)  4(1) 
N(3) 27(1)  14(1) 18(1)  -4(1) 1(1)  -8(1) 
C(1) 23(2)  17(2) 25(2)  9(2) -1(2)  -3(2) 
C(2) 21(2)  17(2) 19(2)  3(1) 5(2)  0(1) 
C(3) 34(2)  30(2) 34(2)  3(2) 13(2)  3(2) 
C(4) 52(3)  28(2) 37(2)  -5(2) 27(2)  -1(2) 
C(5) 62(3)  34(2) 22(2)  -5(2) 10(2)  -17(2) 
C(6) 40(2)  30(2) 23(2)  6(2) -4(2)  -6(2) 
C(7) 27(2)  17(2) 21(2)  5(2) 7(2)  -5(2) 
C(8) 25(2)  18(2) 29(2)  4(2) 7(2)  2(1) 
C(9) 40(2)  23(2) 20(2)  0(2) -2(2)  -9(1) 
C(10) 24(2)  17(2) 22(2)  2(2) 4(2)  -3(2) 
C(11) 26(2)  19(2) 23(2)  -1(2) 1(2)  -3(1) 
C(12) 21(2)  18(2) 20(2)  1(1) 0(2)  -4(1) 
C(13) 22(2)  16(2) 24(2)  0(2) -2(2)  -1(1) 
C(14) 32(2)  23(2) 22(2)  -4(2) 3(2)  -1(2) 
C(15) 32(2)  25(2) 22(2)  3(2) 3(2)  -9(2) 













H(3) 7201 10388 5700 39 
H(3N) 5799 5574 5420 23 
H(3A) 8139 4571 3237 39 
H(4) 7567 3689 2560 47 
H(5) 5714 4512 2200 47 
H(6) 4416 6179 2524 37 
H(8) 4495 8549 3771 29 
H(9A) 5990 9100 4282 33 
H(9B) 7392 8380 4284 33 
H(11A) 6901 8932 5051 27 
H(11B) 7614 7476 5104 27 
H(12) 5127 7984 5489 24 
H(13) 7645 8397 5880 24 
H(14A) 5225 8660 6338 31 
H(14B) 6650 8800 6547 31 
H(15A) 7032 6433 6464 32 
H(15B) 5662 6606 6710 32 
H(16A) 5485 4965 6136 30 





 Table 12.  Hydrogen bonds for ohj328_a  [Å and °]. 
___________________________________________________________________________
_  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
___________________________________________________________________________
_  
 O(3)-H(3)...N(3)#1 0.84 1.91 2.744(3) 172.3 
 N(3)-H(3N)...O(2) 0.99 2.47 3.069(3) 118.5 
 N(3)-H(3N)...O(2)#2 0.99 2.30 3.155(3) 144.0 
 C(8)-H(8)...O(3)#3 0.95 2.23 3.154(3) 164.2 
 C(9)-H(9A)...O(1)#1 0.99 2.48 3.079(3) 118.2 
 C(14)-H(14A)...O(1)#4 0.99 2.54 3.457(4) 153.2 
___________________________________________________________________________
_  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,y+1/2,z    #2 -x+1,-y+1,-z+1    #3 -x+1,-y+2,-z+1       




X-Ray crystal structure data for (176) 3-(2-hydroxy-3- (3-hydroxypiperidin-2-yl) propyl) 




Table 1.  Crystal data and structure refinement for 176. 
Identification code  ohj337_0m_a 
Empirical formula  C16 H22 Br N3 O3 
Formula weight  384.27 
Temperature  108(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.7816(2) Å α = 99.3200(10)°. 
 b = 9.6161(3) Å β = 92.9270(10)°. 
 c = 11.1044(3) Å  = 90.6810(10)°. 
Volume 818.72(4) Å3 
Z 2 
Density (calculated) 1.559 Mg/m3 
Absorption coefficient 3.587 mm-1 
F(000) 396 
Crystal size 0.200 x 0.100 x 0.080 mm3 
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Theta range for data collection 4.040 to 66.717°. 
Index ranges -9<=h<=9, -11<=k<=11, -13<=l<=13 
Reflections collected 21000 
Independent reflections 2869 [R(int) = 0.0422] 
Completeness to theta = 66.717° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.81 and 0.58 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2869 / 0 / 210 
Goodness-of-fit on F2 1.079 
Final R indices [I>2sigma(I)] R1 = 0.0244, wR2 = 0.0571 
R indices (all data) R1 = 0.0269, wR2 = 0.0580 
Extinction coefficient n/a 
Largest diff. peak and hole 0.347 and -0.372 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) 




 x y z U(eq) 
___________________________________________________________________________
_____   
Br(01) 6764(1) 3517(1) 4293(1) 15(1) 
O(1) 332(2) 6318(2) 2920(1) 19(1) 
O(2) 3444(2) 2526(2) 2491(1) 18(1) 
O(3) 2293(2) -556(2) 4652(1) 18(1) 
N(1) 1253(2) 4490(2) 1551(2) 13(1) 
N(2) 2687(2) 4807(2) -225(2) 18(1) 
N(3) 2829(2) 3184(2) 5994(2) 13(1) 
C(1) 1062(3) 5909(2) 1973(2) 14(1) 
C(2) 1801(3) 6846(2) 1213(2) 15(1) 
C(3) 1746(3) 8314(2) 1559(2) 20(1) 
C(4) 2442(3) 9183(2) 825(2) 23(1) 
C(5) 3198(3) 8594(2) -250(2) 22(1) 
C(6) 3279(3) 7162(2) -590(2) 20(1) 
C(7) 2584(3) 6258(2) 141(2) 15(1) 
C(8) 2054(3) 4028(2) 483(2) 17(1) 
C(9) 662(3) 3446(2) 2283(2) 15(1) 
C(10) 2078(3) 3148(2) 3191(2) 13(1) 
C(11) 1416(3) 2147(2) 4008(2) 14(1) 
C(12) 2705(3) 1894(2) 5024(2) 12(1) 
C(13) 2232(3) 617(2) 5615(2) 13(1) 
C(14) 3444(3) 474(2) 6700(2) 17(1) 
C(15) 3502(3) 1825(2) 7638(2) 17(1) 





 Table 3.   Bond lengths [Å] and angles [°] for  ohj337_0m_a. 
_____________________________________________________  
O(1)-C(1)  1.231(3) 
O(2)-C(10)  1.429(2) 
O(2)-H(2)  0.8400 
O(3)-C(13)  1.427(2) 
O(3)-H(3)  0.8400 
N(1)-C(8)  1.380(3) 
N(1)-C(1)  1.381(3) 
N(1)-C(9)  1.473(3) 
N(2)-C(8)  1.282(3) 
N(2)-C(7)  1.393(3) 
N(3)-C(16)  1.491(3) 
N(3)-C(12)  1.504(3) 
N(3)-H(1BR)  0.9776 
N(3)-H(1N)  0.9060 
C(1)-C(2)  1.463(3) 
C(2)-C(3)  1.404(3) 
C(2)-C(7)  1.405(3) 
C(3)-C(4)  1.382(3) 
C(3)-H(3C)  0.9500 
C(4)-C(5)  1.398(3) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.371(3) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.403(3) 
C(6)-H(6)  0.9500 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.517(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.528(3) 
C(10)-H(10)  1.0000 
C(11)-C(12)  1.522(3) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(13)  1.532(3) 
C(12)-H(12)  1.0000 
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C(13)-C(14)  1.517(3) 
C(13)-H(13)  1.0000 
C(14)-C(15)  1.526(3) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-C(16)  1.516(3) 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-H(16A)  0.9900 































































































 Table 4.   Anisotropic displacement parameters  (Å2x 103) for ohj337_0m_a.  The 
anisotropic 
displacement factor exponent takes the form:  -2 2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
___________________________________________________________________________
___  
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________
___  
Br(01) 15(1)  9(1) 22(1)  4(1) 4(1)  0(1) 
O(1) 20(1)  20(1) 18(1)  2(1) 9(1)  2(1) 
O(2) 14(1)  23(1) 16(1)  4(1) 5(1)  1(1) 
O(3) 30(1)  8(1) 16(1)  2(1) 1(1)  -1(1) 
N(1) 14(1)  13(1) 12(1)  5(1) 3(1)  1(1) 
N(2) 24(1)  17(1) 14(1)  2(1) 5(1)  1(1) 
N(3) 19(1)  7(1) 15(1)  2(1) 5(1)  -1(1) 
C(1) 11(1)  16(1) 15(1)  3(1) 0(1)  1(1) 
C(2) 14(1)  16(1) 14(1)  4(1) -1(1)  -1(1) 
C(3) 22(1)  17(1) 20(1)  2(1) 3(1)  1(1) 
C(4) 28(1)  13(1) 27(1)  6(1) 0(1)  -2(1) 
C(5) 24(1)  23(1) 20(1)  11(1) -1(1)  -7(1) 
C(6) 21(1)  26(1) 12(1)  5(1) 2(1)  -3(1) 
C(7) 14(1)  19(1) 13(1)  3(1) -2(1)  -1(1) 
C(8) 20(1)  16(1) 15(1)  1(1) 1(1)  1(1) 
C(9) 16(1)  14(1) 17(1)  7(1) 4(1)  -2(1) 
C(10) 15(1)  12(1) 14(1)  3(1) 4(1)  0(1) 
C(11) 14(1)  12(1) 16(1)  6(1) 3(1)  -1(1) 
C(12) 15(1)  8(1) 13(1)  1(1) 5(1)  0(1) 
C(13) 17(1)  9(1) 15(1)  2(1) 4(1)  -1(1) 
C(14) 22(1)  14(1) 17(1)  5(1) 2(1)  1(1) 
C(15) 22(1)  16(1) 13(1)  3(1) 3(1)  2(1) 













H(1BR) 1674 3326 6292 18 
H(2) 4387 2717 2890 26 
H(3) 2480 -1293 4949 27 
H(1N) 3169 3969 5709 16 
H(3C) 1233 8708 2292 23 
H(4) 2407 10177 1051 27 
H(5) 3665 9197 -754 26 
H(6) 3806 6781 -1321 23 
H(8) 2145 3038 250 20 
H(9A) 313 2561 1734 18 
H(9B) -354 3807 2727 18 
H(10) 2495 4052 3706 16 
H(11A) 359 2538 4380 16 
H(11B) 1099 1231 3495 16 
H(12) 3858 1736 4673 14 
H(13) 1030 715 5890 16 
H(14A) 4615 270 6417 20 
H(14B) 3054 -324 7086 20 
H(15A) 2350 1995 7966 20 
H(15B) 4326 1723 8326 20 
H(16A) 4052 3942 7653 21 





 Table 6.  Hydrogen bonds for ohj337_0m_a  [Å and °]. 
___________________________________________________________________________
_  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
___________________________________________________________________________
_  
 N(3)-H(1BR)...O(1)#1 0.98 1.84 2.807(2) 171.3 
 O(2)-H(2)...Br(01) 0.84 2.39 3.2226(15) 169.5 
 O(3)-H(3)...Br(01)#2 0.84 2.49 3.3256(15) 175.1 
 N(3)-H(1N)...Br(01)#3 0.91 2.42 3.2527(17) 153.3 
 C(9)-H(9B)...Br(01)#4 0.99 2.95 3.852(2) 152.7 
 C(10)-H(10)...Br(01)#3 1.00 2.98 3.959(2) 165.8 
 C(11)-H(11A)...Br(01)#4 0.99 2.96 3.877(2) 153.9 
 C(12)-H(12)...Br(01) 1.00 2.91 3.692(2) 135.7 
 C(13)-H(13)...O(3)#5 1.00 2.62 3.518(3) 149.2 
 C(16)-H(16A)...N(2)#6 0.99 2.65 3.439(3) 137.0 
___________________________________________________________________________
_  
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y+1,-z+1    #2 -x+1,-y,-z+1    #3 -x+1,-y+1,-z+1       
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